Navigation überspringen
Kongressberichte & Archiv
The 22nd ESMO World Congress on Gastrointestinal Cancer - Virtual Congress
Session I: Cancer of the Pancreas and Biliary Tract
Session II: Hepatocellular Cancer
Session III: Esophageal and Gastric Cancer
Session IV: Gastrointestinal Stromal Tumors (GIST); Neuroendocrine Tumors (NET)
Session V: Molecular Screening; Imaging; Artificial Intelligence
Session VI: Colorectal Cancer I
Session VII: Colorectal Cancer II
Session IX: Rectal Cancer
Virtual Edition of the 25th Annual Congress of the European Hematology Association
Presidential Symposium
Plenary Session I
Plenary Session II
Late-Breaking Oral Session - available fromSaturday June 13 8.30 AM
Oral Sessions
Acute Leukemia
ALL:
AML:
Lymphoma
Aggressive Lymphomas
Hodgkin lymphoma - Clinical
Indolent and mantle-cell non-Hodgkin lymphoma:
Chronic Myeloid Neoplasms
CML clinical
MDS:
MPN (Myelofibrosis & Hypereosinophilic Syndrome)
Chronic Lymphoid Neoplasms
CLL:
Multiple Myeloma
Immunology
CART cells
Immunotherapy:
Stem cell transplantation:
Red & White Cell Disorders
Iron in focus
Sickle cell disease:
Thalassemia:
ITP:
Link to Satellite Session - Live Fri 12 Jun 17:30-18:30
e-Poster Presentations
ASCO20 Virtual Scientific Meeting
Studies presented at press briefings
Pre-Meeting Presentation
Press Briefing May 28
Plenary Session Abstracts
Oral Sessions
Breast Cancer I
Breast Cancer II
Brustkrebs Interviews
CNS Tumours
Developmental Therapeutics I
Developmental Therapeutics II
Gastrointestinal Cancer I
Gastrointestinal Cancer II
Genitourinary Cancer I
Genitourinary Cancer II
Gynecologic Cancer
Gynäkologische Karzinomata - Interviews
Head and Neck Cancer
Hematologic Malignancies I
Hematologic Malignancies II
Hematologic Malignancies III
Lung Cancer I
Lung Cancer II
Skin Cancers
Sarcoma
Pediatric Oncology I
Pediatric Oncology II
SAMO Virtual Workshop on COVID19:
Coronavirus/Brustkrebs
AGO MAMMAKARZINOM - State of the Art Meeting 2020
Keynote-Lecture: Fatima Cardoso
Vormittag 1
Vormittag 2
Nachmittag 1
Nachmittag 2
Interviews im Rahmen einer Kooperation von Oncoletter mit Brustkrebs Deutschland e.v.
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Andreas Schneeweiss, Heidelberg, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Volkmar Müller, Hamburg und Wolfgang Janni, Ulm, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Diana Lüftner Berlin, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Christian Jackisch, Offenbach & Andreas Schneeweiss, Heidelberg, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Bernd Gerber, Rostock zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Volkmar Müller und Ute-Susann Albert, Frankfurt, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Achim Rody, Lübeck, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Achim Wöckel, Würzburg und Christoph Thomssen, Halle zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Michael Lux, Erlangen, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit David Krug, Kiel, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Christoph Thomssen, Halle, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Nina Ditsch, München, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Marc Thill, Frankfurt und Michael Untch, Berlin, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Tanja Fehm, Düsseldorf und Elmar Stickeler, Aachen, zum Thema:
Gespräch mit Kerstin Rhiem, Köln, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Jens Huober, Ulm, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Thorsten Kühn, Esslingen und Jens Uwe Blohmer, Berlin, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Hans H. Kreipe, Hannover, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Ingo Bauerfeind, Landshut und Nina Ditsch, München, zum Thema:
Ten Years of ETOP
2nd Zurich Brain Metastasis Symposium
Experimental Studies
Keynote Lectures
Updates on Therapeutic Approaches
Brain Metastasis: Disease Updates
Controversies & Hot Topics in the Diagnosis and Management of CNS Metastasis
SABCS - 42nd Annual San Antonio Breast Cancer Symposium
Press Conferences
Wednesday, Dec. 11
Thursday, Dec. 12
Friday, Dec. 13
General Sessions 1-6
GENERAL SESSION 1:
GENERAL SESSION 2:
GENERAL SESSION 3:
GENERAL SESSION 4:
GENERAL SESSION 5:
GENERAL SESSION 6:
Interviews - Breast Cancer
HER 2-positiver, metastasierter Brustkrebs: HER2CLIMB Studie mit Tucatinib
HER 2-positiver, metastasierter Brustkrebs: DESTINY-Breast01 Studie mit Trastuzumab Deruxtecan
HER 2-positiver Brustkrebs adjuvant: APHINITY Studie, 2. Zwischenanalyse
HER 2-positiver Brustkrebs adjuvant: ATEMPT Studie T-DM1 gegen Paclitaxel plus Trastuzumab
Einsatz von Capecitabine Neo/Adjuvant
GEPARX Studie: Denosumab im Vergleich zu zwei Nab-Paclitaxel Schemata - neoadjuvant
Immuncheckpoint-Inhibitoren: Durvalumab beim metastasierten BC und Pembrolizumab neoadjuvant und adjuvant bei TNBC
pCR bei neoadjuvanter Therapie mit Atezolizumab beim TNBC?
Neues zu CDK4/6 Inhibitoren (HR+ & HER2-)
Wenn der Brust-Tumor weg ist nach neoadjuvanter Therapie: Muss noch operiert werden?
Teil- oder Ganzbrustbestrahlung nach Brust erhaltender Therapie. Was für wen?
Schweizer Expertenrunde mit einigen Highlights vom SABCS:
Round Table mit Brustkrebs Deutschland e.V.
61st ASH Annual Meeting and Exposition
Highlights of the Conference: Statements & Opinions
ALL
Multiples Myelom
Multiples Myelom
Lymphome
Press Briefings
Saturday, December 7:
Saturday, December 7:
Saturday, December 7:
Sunday, December 8:
Monday, December 9 (embargoed until Tuesday 7:30 AM EST):
Late Breaking Abstract Session
Acute Lymphoblastic Leukemia (excluding Transplantation)
Therapeutic Strategies
Novel Therapies
Clinical Studies - Choice of Poster-Abstracts with Asparaginase
CAR T Cells--Refining the Approach
Chemo Immuno and Targets--Improving Combinations in ALL
Acute Myeloid Leukemia (excluding Transplantation)
Clinical Studies: Non-Intensive Therapy
Intensive Upfront Chemotherapy
Treatment of Relapsed/Refractory Disease
Induction and Post-Remission Therapy
New Treatment Strategies
Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs
Novel Targets and Combinations
Chronic Myeloid Leukemia: Therapy
Predictors of TKI Discontinuation and TFR Outcomes
Clinical Trials and Outcomes
Response Monitoring and Prognosis
Myeloproliferative Syndromes
Emerging and Novel Targeted Therapies
JAK Inhibitors and Combination Therapies
Myelodysplastic Syndromes
Combination Therapies
Targeting Gene Mutations in MDS
Lower-Risk MDS and CMML
SAKK POSTER
Myeloma: Therapy, excluding Transplantation
New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias
Novelty in CAR T in Relapsed/Refractory Multiple Myeloma
Therapeutics Questions in Newly Diagnosed Myeloma
Improving the Outcomes of Newly Diagnosed Multiple Myeloma
Novel Therapy for Relapsed Myeloma
CLL (excluding Transplantation)
First Line Treatment
Combination and Novel Treatment
BTK Inhibitors and CAR T Cells in CLL
Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
Follicular Lymphoma: Biomarkers and Clinical Trials
Clinical Trials in Waldestrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas
Mantle Cell Lymphoma: Frontline and Relapsed Therapies
Hodgkin Lymphoma and T/NK Cell Lymphoma
Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma
Immunotherapy Approaches in Hodgkin Lymphoma
Novel Therapies in Peripheral T-cell Lymphomas
Aggressive Lymphoma (DLBC and Other Aggressive B-Cell Non-Hodgkin Lymphomas
Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy
Results from Prospective Clinical Trials: Results from CAR T-Cell Trials
Novel Therapies in Relapsed/Refractory Disease
Results from Retrospective/Observational Studies: Population-Based Outcomes
Results from Retrospective/Observational Studies: Prognostic Markers
Results from Retrospective/Observational Studies: Cellular Therapies
Immunotherapies
Immunotherapies I
Immunotherapies II
Gene Therapy and Transfer
Advancing CAR T Cells: New Biology and Therapeutic Applications
Gene Therapies for Non-Malignant Disorders
CAR-T-Zell Therapie in der Schweiz
Archiv 2019
8. Interdisziplinäres Prostatakarzinom-Symposium 2019
I Grundlagen und Früherkennung
II Lokoregionäre Therapie des Prostatakarzinoms
III Aspekte der Systemtherapie des Prostatakarzinoms
Cancer Academy – Immuntherapie
Jahrestagung 2019 von DGHO, OeGHO, SGMO und SGH+SSH
Pressekonferenz
OnkoZentrum Zürich - Patientenforum 2019
ESMO 2019
Press Briefings
Opening Press Conference
Lung and gynaecological cancers
Breast cancer
Gastrointestinal and genitourinary cancers
SAKK Studien am ESMO 2019
Brustkrebs
Gastrointestinal Cancers
Metastatic Colorectal Cancer (mCRC)
More from BEACON CRC & TAILOR
Metastatic Gastric, Pancreatic & Biliary Cancer
Lung Cancer, Mesothelioma & Head and Neck Cancer
Melanoma
Ovarialkarzinom
Cancer Academy - Kopf-Hals-Tumore
IASLC 2019 World Conference on Lung Cancer (#WCLC19)
Interviews
Press Briefings
Saturday, September 7th Press Briefing
Sunday, Sept. 8th Press Briefing
Monday, Sept 9th (Presidential Symposium Press Briefing)
Tuesday, Sept 10th Press Briefing
4th Zurich Immuno-Oncology Symposium
Keynote Address
Therapeutic Developments I
Therapeutic Developments II
Challenges in Patient Management
Challenges in Optimizing Treatment
Cell-based Therapies
ESMO World Congress on Gastrointestinal Cancer
Press Conferences (News being made available according embargo rules)
Wednesday, 3 July - Opening Press Conference
Thursday, 4 July - Key studies of the day
Friday, 5 July - Key studies of the day
Session II: Cancer of the Pancreas and Biliary Tract
Presentation of Selected GI Cancer Abstracts
Presentation of Selected Rectal Cancer Abstracts
Session VII: Gastric Cancer - Presentation of Selected Abstracts
Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 1
Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 2
Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 1
Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 2
Session XVI: Hepatocellular Cancer - Presentation of Selected Abstracts
Session XX: Colorectal Cancer (Part I) - Presentation of Selected Abstracts & Comments Roger von Moos and Thomas Winder
Second Zurich Lung Cancer Symposium
Lung Cancer Screening and Approach to Small Lesions
Molecular Pathology of Lung Cancer
Development in Stage III NSCLC Disease
The Improvement of Survival in Metastatic NSCLC
The Importance of Clinical Trials
Approach to Oligometastatic Disease
15th International Conference on Malignant Lymphoma (ICML)
Introductory Press Conference
PLENARY SESSION
MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD?
HOW TO APPROACH CLL IN CLINICAL PRACTICE
THE MODERN APPROACH TO MANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA
PET IMAGING
PEDIATRIC LYMPHOMA
RESULTS FROM SINGLE AGENT TRIALS
ONGOING TRIALS
DLBCL: CLINICAL DATA
CLL
TREATMENT WITH NOVEL ANTIBODIES
T-CELL LYMPHOMAS
CLL AND MORE
CHEMOTHERAPY-FREE STRATEGIES
NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS
HIGH RISK LARGE B-CELL LYMPHOMAS
LYMPHOMA PATHOLOGY
HODGKIN LYMPHOMA
FOLLICULAR LYMPHOMA
EXTRANODAL LYMPHOMAS
NEW DATA ON T-CELL AND OTHER LYMPHOMAS
ADVANCES IN CAR T-CELL TREATMENT
NEW DRUG COMBINATIONS
INDOLENT NON-FOLLICULAR LYMPHOMA
24th Congress of EHA
Presidential Symposium
Late-breaking oral presentations (6 best abstracts)
Important presentations at Press Briefings
Friday, June 14, 2019
Saturday, June 15, 2019
Indolent and mantle-cell non-Hodgkin Lymphoma - clinical
Aggressive lymphomas - New agents
Aggressive lymphomas - First line, combination therapy and real-life data - Aggressive non-Hodgkin lymphoma
Hodgkin lymphoma - clinical
Novel agents and therapies for CLL
New stratification and treatment approaches in ALL - including CAR T Cell therapy
Advances in the management of thalassemia
Immunotherapy in relapsed/refractory multiple myeloma
Novel strategies in multiple myeloma
Novel agents for newly diagnosed plasma cell dyscrasias
Myeloma and other monoclonal gammopathies - Clinical
New therapies in AML
Gene therapy, cellular immunotherapy and vaccination - Biology & translational research
Gene therapy, cellular immunotherapy and vaccination - Clinical
Update on clinical trials in MPN
New agents in MPN
Annual Meeting of the American Society of Clinical Oncology 2019
Press Briefings
May 15 Presscast
Press Briefing Saturday June 1:
Press Briefing Sunday June 2:
Press Briefing Monday June 3:
Breast Cancer
Breast Cancer News Interviews
Breast Cancer News Aufzeichnung Live-Stream
Oral & Poster Presentations
Colon Cancer
Oral Presentations
Poster Presentations
Other gastrointestinal Cancer
Oral Presentations
Poster Presentations
Other Gynaecologic Cancers
Head & Neck Cancers
Oral Presentations
Poster Presentations
Lung Cancer
Hauttumore
Urogenital Cancers
Oral Presentations
Poster Presentations
Hematology
Multiple Myeloma & Myelofibrosis
Lymphoma & CLL
ALL
Senologie Update 2019
Teil 1:
Teil 2:
Teil 3:
Teil 4:
ELCC 2019 - European Lung Cancer Congress | ESMO 10-13 April 2019 Geneva, Switzerland
BCC2019
Opening and Award Ceremony:
Session 1: News since St.Gallen 2017
Session 2: Biology of Breast Cancer I: Risk stratification
Session 3: Biology of breast cancer II: Prediction of response
Session 4: Risk stratification and prevention in ductal in situ carcinoma
Special lecture I and II
Session 5: New pathways with potential impact in the treatment of early breast cancer
Session 6: Treatment tailoring according to pathology and biology
Session 7: Surgery of early breast cancer
Session 8: Radiotherapy of early breast cancer
Special lecture III
Session 9: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit I
Session 10: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit II
GenomicHealth interactive satellite symposium in conjunction with the 16th St Gallen International Breast Cancer Conference
Nanostring Satellite Symposium: Recent Breakthroughs for HR+/HER2- Early Breast Cancer Patients:
Interviews (in German): Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
Three SAKK Posters
45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Interviews
Presidential Symposium
GS2-2 - IMPROVED SURVIVAL OF AML- AND MDS-PATIENTS AFTER TREOSULFAN-BASED COMPARED TO REDUCED‑INTENSITY BUSULFAN-BASED CONDITIONING-REGIMEN FOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION: FINAL RESULTS OF A PROSPECTIVE RANDOMISED PHASE-III-TRIAL
GS2-3 - GRAFT-VERSUS-LEUKEMIA EFFECT AFTER HAPLO-IDENTICAL STEM-CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN AML- NO ASSOCIATION WITH GRAFT-VERSUS-HOST-DISEASE: A STUDY OF THE ACUTE LEUKEMIA WORKING PARTY OF EBMT
GS2-4 - SEQUENTIAL CD19- AND CD22-CART CELL THERAPIES FOR RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 10-MONTH MEDIAN FOLLOW-UP
GS2-5 - ALLOGENEIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS VERSUS MATCHED OR MISMATCHED 9/10 UNRELATED DONORS IN ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION
GS2-6 - LOW-DOSE INFUSIONS OF CD45RA DEPLETED DONOR LYMPHOCYTES AFTER TCR ALPHA/BETA-DEPLETED TRANSPLANTATION IN PATIENTS WITH NON-MALIGNANT DISORDERS
GS2-7 - CELL-MEDIATED IMMUNOGENICITY OF THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) IN ADULT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED ZOE-HSCT CLINICAL TRIAL
Oral Session 9: Late-breaking abstracts
OS9-1 - COMPARABLE OUTCOME AFTER 10/10 AND 9/10 HLA-MATCHED UNRELATED DONOR STEM CELL TRANSPLANTATION (HSCT) USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) FOR GVHD PROPHYLAXIS, ON BEHALF OF THE ALWP-EBMT.
OS9-2 - MYELOABLATIVE CONDITIONING FOR FIRST ALLOGENEIC HSCT IN PEDIATRIC ALL: FTBI OR CHEMOTHERAPY? - AN UPDATE OF THE RETROSPECTIVE MULTICENTER EBMT-PDWP STUDY
OS9-3 - THE DETECTION OF THE SOLUBLE EBV ZEBRA PROTEIN AS A NEW PREDICTIVE BIOMARKER FOR PTLD
OS9-4 - EFFECTIVE CANCER IMMUNOTHERAPY WITH ERBB2-CAR-ENGINEERED CYTOKINE-INDUCED KILLER (CIK) CELLS IN HIGH-RISK SOFT TISSUE SARCOMAS
OS9-5 - GENESIS - A PHASE III RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, EVALUATING SAFETY AND EFFICACY OF BL-8040 AND G-CSF IN MOBILIZATION OF HCS´S FOR AUTOLOGOUS TRANSPLANTATION-MULTIPLE MYELOMA
OS9-6 - REAL LIFE EXPERIENCE IN THE TREATMENT OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT ALL PATIENTS USING COMMERCIALLY AVAILABLE CAR-T-CELLS
How Do I... manufacture T cells for cellular therapies
HDI1-1 - Manufacturing of virus-specific T cells at an academic center
HDI1-2 - CAR T manufacturing in an academic setting
HDI1-3 - Low-dose memory T cell DLI for infection prophylaxis
How Do I... manage patients after CAR T-cell therapy.
HDI8-1 - Lymphoma, CLL and ALL
HDI8-2 - Myeloma patients
HDI8-3 - From a nurse's perspective
New developments in the field of CAR cell therapy
P2-1 - State of the art for ex-vivo manufactured autologous CAR T-cells
P2-2 - Simultaneous targeting of CD19 and CD22 with a bicistronic CAR - preliminary results of the AMELIA study
P2-3 - Off-the-shelf CAR NK cells for the treatment of hematologic malignancies
P2-4 - CAR T-cells against solid tumors: TRUCKs on the road
AGO MAMMAKARZINOM - State of the Art Meeting 2019
Vormittag 1
Vormittag 2
Nachmittag 1
Nachmittag 2
Interviews: Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
First Zürich Precision Oncology Symposium
Speakers
Molecular Testing and Molecular Tumor Board
Keynote address
Precision Oncology for Solid Tumors 1/Ongoing Research Activities 1
Precision Oncology for Solid Tumors 2
Precision Oncology for Hematologic Malignancies
Precision Oncology for Solid Tumors 2/Ongoing Research Activities 2
The Gastrointestinal Cancers Symposium 2019
ASSOC.PROF. PD DR. GERALD PRAGER, WIEN: Cancers of the Esophagus and Stomach - the Highlights
General Session 1:
General Session 2:
Rapid Abstract Session A:
Breakout Session: Palliation of Esophago-Gastric Malignancies
Oral Abstract Session A:
General Session 3:
Poster Walks:
Rapid Abstract Session B:
Breakout Session: Novel Innovations in Pancreatic and Hepatobiliary Malignancies
Welcome and General Session 4:
General Session 5:
Keynote Lecture: Kelly McMasters
ASSOC.PROF. PD DR. GERALD PRAGER, WIEN: Cancers of the Pancreas - the Highlights
Oral Abstract Session B:
General Session 6:
Poster Walks:
liposomal irinotecan (nal-IRI) 2nd line & neoadjuvant
PD DR. MED. DOMINIK MODEST, MÜNCHEN - Colon Cancer - Personal Highlights
Rapid Abstract Session C:
Welcome and Keynote Lecture:
Breakout Session: The Latest Updates on HIPEC for Gastrointestinal Cancers
General Session 7:
Oral Abstract Session C:
Poster Walks:
General Session 8:
General Session 9:
POSTER SESSIONS A,B,C
Trials in Progress Poster Session A, B, C
Presentations with trifluridine/tipiracil (FTD/TPI) at the Gastrointestinal Cancers Symposium
Archiv 2018
SABCS - 41st Annual San Antonio Breast Cancer Symposium
Press Conferences
Wednesday, Dec. 5, Press Conference 1
Wednesday, Dec. 5, Press Conference 2
Thursday, Dec. 6 Press Conference
Friday, Dec. 7 Press Conference
Schweizer Poster am SABCS
Interviews - Breast Cancer
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Achim Rody, Lübeck
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle/Saale
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Priv.-Doz. Dr. med. Hans-Christian Kolberg in Bottrop
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Thorsten Kühn, Esslingen
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Wilhelm Braun, München
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Sibylle Loibl, Frankfurt
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Michael Untch, Berlin-Buch
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. Rachel Würstlein, München
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Jörg Schilling, Berlin
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Priv.-Doz. Dr. med. Hans-Christian Kolberg, Bottrop
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Lothar Müller, Onkologie Unterems
Schweizer Expertenrunde mit einigen Highlights vom SABCS:
Round Table mit Brustkrebs Deutschland e.V.
General Sessions
GENERAL SESSION 1:
GENERAL SESSION 2:
GENERAL SESSION 3:
GENERAL SESSION 4:
GENERAL SESSION 5:
GENERAL SESSION 6:
American Society of Hematology (ASH) 60th Annual Meeting and Exposition
Statements & Opinions from some Highlights of the Conference
PD Dr. med. Nicolas Bonadies, Bern
Prof. Dr. med. Christoph Driessen, St. Gallen
Prof. Dr. med. Christoph Renner, Zürich
Press Briefings
Saturday December 1
Sunday December 2
Monday December 3
Late-Breaking Abstracts Session
Myeloma: Therapy and upfront autologous Transplantation
Novel Antibody Combinations in Myeloma
Novel Targeted Combinations in Myeloma
Antibodies and Targeted Therapies
Novel Proteasome Inhibitors
Immunotherapies in Plasma Cell Disorders
Immunotherapy
Upfront Autologous Transplantation
Choice of Myeloma Posters
AML
Acute Myeloid Leukemia - Clinical Studies
Acute Myeloid Leukemia - Commercially Available Therapy, excluding Transplantation:
Acute Myeloid Leukemia - Novel Therapy, excluding Transplantation
Lymphoma
Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies
Acute Lymphoblastic Leukemia: Clinical Studies & Therapy Excluding Transplantations
Improving Outcomes with Cellular Therapy
Improving Frontline Therapy in ALL
Chimeric Antigen Receptor T-cell therapy in ALL: What Is Next?
Targeted Therapy in ALL: Immunotherapy and Beyond
CLL: Therapy, excluding Transplantation:
Measurable Residual Disease in CLL: Moving Towards a Cure
Cellular Therapy and Immunomodulation in CLL
Advances in CLL Using Novel Combination Therapy
Chronic Myeloid Leukemia: Therapy
Epidemiology, Prognosis, and Real Life Care
First Line Trials and Prognostic Factors of Treatment-Free Remission
TFR Failure, Resistance, and New Drug Development
Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics, Prognosis and Prediction
Novel Therapeutics I
Novel Therapeutics II
Prognosis and Prediction
Scientific, medical, clinical, relevant “asparaginase” related Presentations
Health Services & Outcome Research—Malignant Diseases
Clinical Trials for Hemophilia and Using CAR T Cells
Thalassemia and Globin Gene Regulation
Cancer Academy: Sarkome, Früherkennung, Diagnose und Behandlung
ESMO 2018 Congress
Press Briefings
Breast Cancer
Ovarian Cancer
Prostate & Kidney Cancers
Head & Neck Cancer
All ESMO 2018 Press Releases
Interviews
Interviews - Breast Cancer
Statement Summary GIT-Cancers
Statements Colorectal Cancer
Statements Gastric Cancer
Statements Lung Cancer
Statement Renal Cell Carcinoma
Links to selected presentations and abstracts
Presidential Sessions
Selection of Posters
Cancer Academy - Blut- und Lymphdrüsenkrebs
Comprehensive Cancer Center Zürich: Third Zurich Immuno-Oncology Symposium
Keynote address
Clinical results, patient cases and future developments I
Clinical results, patient cases and future developments II
Clinical results, patient cases and future developments III
Developments in immunotherapy
20th World Congress on Gastrointestinal Cancer (WCGIC 2018)
Session I: Welcome with Selected Abstracts
Session II: Cancer of the Pancreas and Biliary Tract - Selected Abstracts
Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer
Pancreatic Cancer: Poster Session
Session VII: Gastric Cancer: Presentation of selected abstracts
Session VIII: Diseases and Cancers of the Liver: Presentation of a selected abstract
Session XI: Presentation of Selected Abstracts: Colorectal Cancer
Session XX: Colorectal Cancer: Presentation of selected abstracts
23rd Congress of EHA
Presidential Symposium
Plenary Session Abstracts
Press Briefings
Press Briefing Day 1
Press Briefing Day 2
Important AML Presentations
IDHm and BCL2 inhibitors in AML
One AML Poster
Important CLL Presentations
Important Multiple Myeloma Presentations
Advances in front-line treatment of newly diagnosed multiple myeloma
New therapeutic strategies to improve the outcome of relapsed/refractory plasma cell disorders
Multiple Myeloma Poster Presentations
One Multiple Myeloma Late Breaking Abstract
Important Lymphoma Presentations
Thalassemia (2 Presentations) & MDS (1 Presentation)
Annual Meeting of the American Society of Clinical Oncology 2018
Highlights of the day
Sunday
Monday
Tuesday
Press Briefings
May 16 Presscast
Press Briefing 1 Friday June 1:
Press Briefing 2 Saturday June 2:
Press Briefing 3 Sunday June 3:
Press Briefing 4 Monday June 4:
Breast Cancer
Breast Cancer News from Oral Sessions
Breast Cancer News from Poster Sessions
Breast Cancer News Interviews
Colon Cancer
Colon Cancer News from Poster Sessions
Lung Cancer
Lung Cancer News from oral sessions
Lymphoma
Lymphoma News Oral Sessions
Lymphoma News Poster Sessions
Merkel-Cell Carcinoma
Myeloid Diseases
Myeloid Diseases News from Oral Sessions
Myeloid Diseases News from Poster Sessions
Other Hematologic Malignancies
Pancreatic Cancer
Pancreatic Cancer News from Oral Sessions
Pancreatic Cancer News from Poster Sessions
Urologic Cancers
Renal Cancer
ESMO Preceptorship on Colorectal Cancer 2018
SENOLOGIE update 2018
Prophylaktische Mastektomie - Moderation: M. Knauer, St. Gallen
Psychosoziale Konsequenzen des Mammakarzinoms - Moderation: E. Sarasin, Zürich
Update Systemtherapie - Moderation: U. Breitenstein, Zürich
Varia - Moderation: E. Saurenmann, Zürich
Cancer Academy - Darmkrebs
AACR Annual Meeting 2018, April 14-18,
Highlights presented at the Press Conference Sunday, April 15
Highlights presented at the Press Conference Monday, April 16
Highlights presented at the Press Conference Tuesday, April 17
ELCC 2018 (European Lung Cancer Congress)
Highlights - Press Releases
Interviews
Conference Highlights
Interviews in Cooperation with the Video Journal of Oncology - Part 1
SAKK 16/14 – Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
11th European Breast Cancer Conference (EBCC-11)
Press conferences
Important News
Interviews
PD Dr. med. Christian Kolberg, Bottrop
Prof. Dr. med. Thorsten Kühn, Esslingen
Prof. Dr. med. Nadia Harbeck, München
St. Gallen International Gastrointestinal Cancer Conference Primary Therapy of Early GI Cancers -
Session 1: Oesophago-Gastric Cancer: One Disease or Separate Entities?
Session 2: Treatment of Oesophago-Gastric Cancer: Setting the Stage – Who Benefits from Multimodal Therapy
Session 3: Treatment Modalities for Oesophago-Gastric Cancer
Session 4: Special situation I: Signet Ring Cell Cancer
Keynote: Hereditary Gastric Cancer
New Therapy Options by metastatic Colorectal Cancer
Session 5: Special situation II: Limits of Curative Approaches to Metastatic Oesophago-Gastric Cancer
Session 6: Ready for Practice?
EORTC Gastrointestinal Tract Cancer Group:
Cancer Academy - Prostatakrebs
Promoting Self-efficacy with Digital Tools
Welcome (German)
Promoting patients’ self-efficacy: How can it be successful? (German)
United Kingdom’s perspective on the use of digital solutions to improve cancer patients’ self-efficacy
Presentation of selected digital and patient-oriented applications
Consilium: Patient-centered communication for improved self-efficacy and quality of life
STREAM – Ein online Programm zur Unterstützung bei Belastung während einer Krebserkrankung
Symptom Navi: Förderung des Selbstmanagements von Symptomen bei Krebs
Entspannung und Achtsamkeit für Krebspatienten mit Hilfe einer App (CanRelax)
FertiOnco – an online approach to facilitate decision making in young female cancer patients regarding fertility preservation
The use of patient-reported outcomes to improve outcomes and quality in cancer care
Digital solutions for cancer patients: reach, (cost-) effectiveness and implementation
Discussion and Closing remarks (German)
Gastrointestinal Cancers Symposium Jan 18-20, 2018 San Francisco, California
Cancers of the Esophagus and Stomach
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Videostatements
Studies presented in oral sessions
Posters
Posters
Cancers of the Colon, Rectum, and Anus
Videostatement
Studies presented in oral sessions
Choice of Posters
Archiv 2017
59th ASH Annual Meeting and Exposition
Late-Breaking Abstracts Session
AML
Oral Sessions
Multiple Myeloma
Oral Sessions
Choice of Posters
Lymphoma
Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
Hodgkin Lymphoma and T/NK Cell Lymphoma
CLL: Therapy, excluding Transplantation:
Press Conferences
Novel Approaches to Hemophilia and Venous Thromboembolism Care
Engineering Solutions to Treat Inherited Blood Disorders
Enhancing Care in Hematologic Malignancies through Targeted Therapies
Driving Outcomes in Lymphoma, Myeloma with CAR T-Cell Therapies
Late-Breaking Abstracts
Interviews
Statement Christian Taverna, Münsterlingen
Statement Thorsten Zenz, Zürich
40th Annual San Antonio Breast Cancer Symposium (SABCS)
General Sessions
GENERAL SESSION 1:
GENERAL SESSION 2:
GENERAL SESSION 3:
GENERAL SESSION 4:
GENERAL SESSION 5:
GENERAL SESSION 6:
Press Conferences
Wednesday December 6 @ 7:15 a.m.
Wednesday December 6 @ 12:15 p.m
Thursday December 7 @ 7:30 am
Friday December 8 @ 7:30 am
Interviews & Brustkrebs Deutschland Round Table & SAKK Roundtable
Roundtable Brustkrebs Deutschland
Roundtable mit Experten aus der Schweiz
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Peyman Hadji, Marburg
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Peyman Hadji, Marburg
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin (Kopie)
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Stefan Buchholz, Regensburg
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Thorsten Kühn, Esslingen
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Dr. phil. Ute Berndt, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr.med. Michael Untch, Berlin-Buch
Cancer Academy – Hirntumoren
7. Interdisziplinäres Prostatakarzinomsymposium
Grundlagen
Lokalisiertes & oligometastatisches Prostatakarzinom
Systemtherapien Prostatakarzinom
Advanced Breast Cancer 4th ESO-ESMO International Consensus Conference
Cancer Academy – Brustkrebs
ESMO 2017 Congress
Breast Cancer Highlights
Neoadjuvante Therapie bei luminalem, triple negativem oder HER2 positivem Brustkrebs
Luminaler Brustkrebs - wer braucht Chemotherapie?
CDK4-6 Inhibitoren beim metastasierten Brustkrebs
Abstract LBA10_PR ‘Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)’
Abstract 1472P_PR ‘Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients’
Gastrointestinal Carcinoma Highlights
Colorectal Cancer
Gastric Cancer
Head & Neck Cancer Highlights
PD Dr. med. Sacha Rothschild comments Head&Neck Cancer Studies
Abstract LBA45_PR ‘Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial’
1065P - 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis
1. First line Cetuximab and Cisplatin with or without Paclitaxel/2. The observational ENCORE study: Cetuximab + platinum-based therapy
Lung Cancer Highlights
Prof. Martin Reck
PD Dr. AlessandraCurioni-Fontecedro
PD Dr. AlessandraCurioni-Fontecedro
Prof. Dr. med.Solange Peters
Alectinib: ALEX and ALUR trials show CNS benefit in NSCLC
Melanoma & Merkel Cell Carcinoma Highlights
Prof. Dr. med. Reinhard Dummer, Zurich
Prof. Dr. med. Olivier Michielin, Lausanne
Ovarian Cancer Highlights
Urogenital Cancer Highlights
Richard Cathomas, Chur, comments on the urogenital Carcinoma Highlights
Abstract LBA37_PR – ‘Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): mature results from the phase 3 KEYNOTE-045 trial’
Late breaking news
Opening Press Conference
LBA Press Conference: Lung cancer
Press Conference: Facing the challenges of life after cancer
LBA Press Conference: Breast cancer, Gynaecological cancers, Genito-urinary cancers
LBA Press Conference: Melanoma cancer
Wrap-Up press conference/Best of ESMO2017
Cancer Center Zürich Second - Zurich Immuno-Oncology Symposium
Welcome
Essentials of tumour immunology and immunotherapies
Clinical results, patient cases and future developments I
Clinical results, patient cases and future developments II
Clinical results, patient cases and future developments III
Management of toxicities
ESMO 19th World Congress on Gastrointestinal Cancer
Cancer of the Pancreas
Session II: Cancer of the Pancreas & bile Ducts
Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology
Optimizing the Continuum of Care for Patients with Pancreatic Cancer: A Case Study-Based Debate
Interview mit Prof. Gerald Prager, Wien
Colon Cancer Highlights
Session XIX: Colorectal Cancer
Prof. Dr. med. Bernhard Pestalozzi, UniversitätsSpital Zürich:
Die besonderen Bedürfnisse von Kindern und Jugendlichen mit Krebs
14 The International Conference on Malignant Lymphoma (ICML)
Interviews & Introductory Press Conference
Introductory Press Conference
Lymphoma Therapy
Oncoletter Interviews in cooperation with VJHEMONC
Satellite Symposia
THE FIRST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE
CHEMOTHERAPY IN INDOLENT LYMPHOMA - DYING OR WELL ALIVE?
ASCO Annual Meeting 2017
ASCO Press Conferences
ASCO Annual Meeting 2017 Presscast May 17
ASCO Annual Meeting 2017 Presscast June 2
ASCO Annual Meeting 2017 Presscast June 3 Part 1
ASCO Annual Meeting 2017 Presscast June 3 Part 2
ASCO Annual Meeting 2017 Presscast June 4
ASCO Annual Meeting 2017 Presscast June 5
Online-Programm verbessert die Lebensqualität von Krebspatienten
Highlights Mammakarzinom
Brustkrebs Deutschland: Experten-Roundtable vom ASCO Annual Meeting 2017
HER2-positiver, primär metastasierter Brustkrebs
HER2-positiver metastasierter Brustkrebs
PARP-Inhibitoren bei Brustkrebs
Abemaciclib bei Brustkrebs-Hirnmetastasen
HER2-positiver, primär metastasierter Brustkrebs
Scalp-Cooling - Chemo ohne Haarverlust?
CDK 4-6 Inhibitoren: Palbociclib, Ribociclib, Abemaciclib
Ergebnisse der Aphinity-Studie für HER 2 neu-positiven Brustkrebs adjuvant
Stellungnahme zur Relevanz von Studienendpunkten und deren Akzeptanz am runden Tisch: Wir alle müssen umdenken!
Finale Ergebnisse der PlanB-Studie für klinische Hochrisikopatientinnen bzw. mit mittlerem bis hohem Risiko nach Genexpressionstest
Short-HER-Studie:Sind 9 Wochen Trastuzumab nicht schlechter als 1 Jahr?
I-Spy 2-Studie: Immuntherapie mit Pembrolizumab plus Standard neoadjuvante Therapie für Hochrisikopatientinnen
Highlights Ovarialkarzinom
LION Studie: Rolle der Lymphknotenentfernung bei Erstoperation des Eierstockkrebs
DESKTOP 3 Studie: Erneute OP beim Eierstockkrebs Rezidiv
Immuntherapie bei Vulva-, Zervix- und Ovarialkarzinom: gibt es schon Einsatzmöglichkeit?
PARP-Inhibitoren beim Eierstockkrebs: welcher, wann und wie lange?
Head & Neck Cancer Highlights
Highlights Head&Neck
Statements Sacha Rothschild, Jean Bourhis & Marco Merlano
Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)
Highlights Gastrointestinaltumoren
Upper GIT
Colon Cancer
Pancreatic Cancer
Haematologic Malignancies
ELCC 2017 Genf
Cancer Academy – Lungenkrebs: Früherkennung, Diagnose und Behandlung
SENOLOGIE update 2017
Radiologie - Moderation: F. Dammann, Zürich
Genetik - Moderation: R. Morant, Rapperswil
Qualitätssicherung in der Senologie - Moderation: C. Rageth, Zürich
Operative Therapie - Moderation: C. Tausch, Zürich
Das metastasierte Mammakarzionom - Moderation: A. Müller, Winterthur
Varia - Moderation: D. Fink, Zürich
15th St.Gallen International Breast Cancer Conference
Symposium Thoracic Oncology – Guidelines and Beyond
Screening
Inquiring the molecular tumor characteristics
Shanghai meets Zürich
Treatment options in localized NSCLC
Multimodality approaches in rare thoracic tumors
Metastatic disease
Archiv 2016
Das elektronische Patientendossier: das Genfer Beispiel der Integration eines Spitals in eine Referenzgemeinschaft
IASLC 17TH WORLD CONFERENCE ON LUNG CANCER
Fachpressemitteilungen
Lungenkrebs-Weltkongress in Wien: Aktive Prävention, akkurate Diagnostik, aktuelle Fortschritte in der Behandlung
Mutations-Diagnostik setzt sich bei Lungenkrebs durch
Mikro-RNA zur Prognosebestimmung bei Mesotheliom-Erkrankungen
Therapeutische Impfung gegen Lungenkrebs:
Zweite Therapiechance für Lungenkarzinompatienten
58th Annual Meeting of the American Society of Hematology
PRESS CONFERENCES
Developing Novel Therapies and Unique Delivery Methods to Improve Treatment for Bleeding Crises, Leukemia
Revolutionizing Sickle Cell Disease Care in the United States and Abroad
Improved Outcomes in Leukemia, Trauma Settings with Personalized Medicine Approaches
Choice of ASH presentations
616: Acute Myeloid Leukemia
Lymphoma
642. CLL
653. Myeloma
637. Myelodysplastic Syndromes
904. Outcomes Research
112. Thalassemia and Globin Gene Regulation
Interviews Best of ASH (Multiples Myelom, Lymphome)
Zürich, 25. November 2016: 6. Treffen von Krebspatientinnen und -patienten
ESMO-Congress, Oct 07-11, 2016 - Copenhagen, Denmark
Press Conferences
Friday 7 October - Opening Press Conference
Saturday 8 October Press Conference 1: Late Breaking Trials
Sunday 9 October Press Conference 2: Late Breaking Trials
Monday 10 October Press Conference 3: Late Breaking Trials
More Highlights
Metastatic Colorectal Cancer
Cancer Center Zürich First Zurich Immuno-Oncology Symposium
Essentials of tumour immunology and immunotherapies
Clinical results, patient cases and future developments I
Clinical results, patient cases and future developments II
Clinical results, patient cases and future developments III
Management of toxicities
Radiotherapy
Das elektronische Patientendossier als zentrales Instrument der interprofessionellen Zusammenarbeit in integrierten Versorgungsorganisationen
WCGIC - 18th World Congress on Gastrointestinal Cancer
Metastatic & non-metastatic Colorectal Cancer
Statements Ulrich Güller, Andreas Wicki, Thomas Winder
ESMO PRESS RELEASES
Regorafenib shows significant survival gains in refractory liver cancer
Anti-interleukin-1 alpha antibody MABp1 improves outcomes significantly over placebo
Chemoradiotherapy after surgery for gastric cancer shows similar outcomes to post-operative chemotherapy.
Anti-PD-L1 immunotherapy shows response in microsatellite-stable metastatic colorectal cancer in combination with MEK inhibition
Satellite Symposia
Developing a continuum of care for patients with metastatic pancreatic cancer: A case study-based debate
mCRC Myth-Busters reloaded: More facts for optimal patient benefit!
Zürich, 1. Juli 2016: 5. Treffen von Krebspatientinnen und -patienten
Bern, Donnerstag 29. Juni 2016: Den Patienten integrieren - ein Symposium der Nationale Strategie gegen Krebs:
The 21st EHA Annual Congress
EHA Highlights presented at the press conference
Friday June 10
Saturday June 11
36. Jahrestagung Deutsche Gesellschaft für Senologie 25.–28. Mai 2016, Dresden
Das Wichtigste vom Tage
Lunchsymposium: Genomic Health – Oncotype DX
Interviews
SENOLOGIE update 2016
Diagnostik - Moderation: M. Bürge, Zürich
Operative Therapie - Moderation: C. Tausch, Zürich
Über- oder Untertherapie? - Moderation: D. Fink, Zürich
Update Onkologie - Moderation: H-J. Senn, St. Gallen
Varia - Moderation: E. Saurenmann, Zürich
ELCC 2016 | European Lung Cancer Conference - ESMO
News
Osimertinib given as first-line treatment may alter biology of EGFR mutated non-small-cell lung cancer
Immunotherapy with live bacterium improves response rate in malignant pleural mesothelioma
Patients with EGFR expressing non-small-cell lung cancer benefit most from necitumumab added to chemotherapy
Studies confirm benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer
Interviews
3rd Gastrointestinal Cancer Conference
Thursday March 10
Session 1: Cystic Neoplasms of the Pancreas
Session 2: Biliary Tract - Extrahepatic Cholangiocarcinoma I
Keynote I: Molecular biology of pancreatic cancer
Session 3: Biliary Tract - Extrahepatic Cholangiocarcinoma II
Session 4: Cancer of the Ampulla of Vater
Friday March 11
Session 5: Understanding Pancreatic Cancer
Session 6: Resectable Pancreatic Cancer
Satellite symposium organized by Celgene
Session 7: Borderline Resectable Pancreatic Cancer
Session 8: Improving Outcome in Pancreatic Cancer
Symposium Nationale Strategie gegen Krebs:
WEF DAVOS: Cancer Moonshot: A Call to Action
Archiv 2015
SG-PRO 2015: 6. Interdisziplinäres Prostatakarzinomsymposium
I Grundlagen
II Das nodal positive Prostatakarzinom
III Metastasiertes Prostatakarzinom - neue Therapiemöglichkeiten
The European Cancer Congress 2015, Vienna September 25-29, 2015
Press Conference Highlights
Friday 25 September (09.30 hrs) in German
Friday 25 September (16.30 hrs) in English
Saturday 26 September (12.30 hrs) in English
Sunday 27 September (08.30 hrs) in English
Monday 28 September (11.30 hrs) in English
Statements & Interviews
15TH INTERNATIONAL MYELOMAWORKSHOP - SEPTEMBER 23-26, 2015
Press Conference Highlights
DIAGNOSTIC AND RESPONSE CRITERIA
NEWLY DIAGNOSED MULTIPLE MYELOMA YOUNG PATIENTS
RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
NEWLY DIAGNOSED MULTIPLE MYELOMA ELDERLY PATIENTS
IMMUNOTHERAPY
SPECIAL CONDITIONS
VIDEO-INTERVIEWS mit Christoph Driessen und Christian Taverna
WCGIC - 17th World Congress on Gastrointestinal Cancer
Metastatic Colorectal Cancer
Session XIX: Metastatic Colorectal Cancer
More Highlights in mCRC
Evaluating 1st-line treatment strategies for RAS WT mCRC
More Highlights
Multimodal management of patients with advanced cancer and cachexia
35. Jahrestagung Deutsche Gesellschaft für Senologie 25.–28. Juni 2015 Leipzig
Das Wichtigste vom Tage
Interviews
13th International Conference on Malignant Lymphoma
Highlights from 13-ICML
Plenary Session, June 17
Mundipharma Satellite Symposium at 13-ICML
Press Conference
SENOLOGIE update 2015
Radiologie - Moderation: R. Kubik, Baden
Brustzentren und Ärztenetzwerk - Moderation: C. Rageth, Zürich
Genetisches Mammakarzinom - Moderation: U. Breitenstein, Zürich
Update Therapie - Moderation: S. Aebi, Luzern
Varia - Moderation: C. Tausch, Zürich
14 th St. Gallen International Breast Cancer Conference
Interviews mit Fachleuten aus dem Bereich Brustkrebs
Christoph Thomssen, Halle(Saale) im Interview mit Doris C. Schmitt von Brustkrebs Deutschland e.V.
Christoph Thomssen, Halle(Saale) im Interview mit Doris C. Schmitt von Brustkrebs Deutschland e.V.
Michael Untch, Berlin-Buch im Interview mit Renate Haidinger, Brustkrebs Deutschland e.V.
Michael Untch, Berlin-Buch im Interview mit Renate Haidinger, Brustkrebs Deutschland e.V.
Ingo Bauerfeind, Landshut im Interview mit Renate Haidinger, Brustkrebs Deutschland e.V.
Ingo Bauerfeind, Landshut im Interview mit Renate Haidinger, Brustkrebs Deutschland e.V.
Ingo Bauerfeind, Landshut im Interview mit Renate Haidinger, Brustkrebs Deutschland e.V.
Christian Jackisch, Offenbach, im Interview mit Doris C. Schmitt von Brustkrebs Deutschland e.V.
Nadia Harbeck, München, im Interview mit Doris C. Schmitt von Brustkrebs Deutschland e.V.
Nadia Harbeck, München, im Interview mit Doris C. Schmitt von Brustkrebs Deutschland e.V.
Wednesday, 18 March 2015
Satellite symposium Nanostring Technologies
Opening ceremony and conferment of St.Gallen International Breast Cancer Award 2015 & Opening address by the St. Gallen 2015 Award winner
Session 1:
Session 2: Biology of breast cancer I:
Thursday, 19 March 2015
Session 3: Biology of breast cancer II:
Session 4: Biology of breast cancer III:
Session 5: Bridging clinic with biology:
Session 6:
Session 7:
Session 8:
Friday, 20 March 2015
Session 9:
Session 10: Radiotherapy:
Session 11: Adjuvant systemic treatment for individual patients I:
Session 12: Adjuvant systemic treatment for individual patients II:
Session 13: Adjuvant systemic treatment for individual patients III:
Saturday, 21 March 2015
Session 14:
Archiv 2014
ETOP Podium Discussion - Topics in Treatment of Lung Cancer
ESMO 2014, Madrid 26 - 30 September 2014
Presidential Symposium 1
Sandra Swain, Washington Cancer Institute, United States
Johan F. Vansteenkiste, University Hospitals Leuven - Campus Gasthuisberg, Belgium
Tony Mok, The Chinese University of Hong Kong, China
Presidential Symposium 2
Grant McArthur, Peter MacCallum Cancer Centre, Melbourne, Australia
Caroline Robert, Gustave Roussy, France
Jeffrey Weber, H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States
Melanoma
H. Kluger, M. Sznol, M. Callahan, M. Postow et al.
M. Taylor, J. Sosman, R. Gonzalez, M. Kittaneh et al.
O. Michielin (Lausanne, Switzerland)
A. Eggermont, V. Chiarion-Sileni, J. Grob, R. Dummer et al.
Anti-EGFR or anti-VEGF in first-line RAS wild-type metastastic CRC patients
H. Lenz, D. Niedzwiecki, F. Innocenti, C. Blanke et al.
A. Venook, D. Niedzwiecki, H. Lenz, M. Mahoney et al.
S. Stintzing, D. Modest, L. Fischer von Weikersthal, T. Decker et al.
Interview with PD Dr. med. Gunnar Folprecht, Universitätsklinikum Carl Gustav Carus, Dresden
Interview with Prof. Heinz-Josef Lenz, M.D., FACP, USC Norris Comprehensive Cancer Center, Los Angeles, USA
Interview with Prof. Dr. med. Volker Heinemann, Klinikum der Universität München, Klinikum Großhadern, München, Germany
Press briefings with Webcasts
Friday, 26 September 2014
Saturday, 27 September 2014
Sunday, 28 September 2014
Monday, 29 September 2014
Tuesday, 30 September 2014
1. Schweizer Krebskongress
Behandlungspfad: Schlagwort oder Realität?
Interdisziplinäre/interprofessionelle Zusammenarbeit
Nationale Strategie gegen Krebs: Erfahrungsbericht
Schlussvotum und Fazit
Interviews
"Wissen ist (m)eine Chance" eine Veranstaltung zum Thema "Metastasierter Brustkrebs"
WCGIC - 16th World Congress on Gastrointestinal Cancer
Metastatic Colorectal Cancer
More Highlights
34. Jahrestagung Deutsche Gesellschaft für Senologie 19.–21. Juni 2014 Berlin
Das Wichtigste vom Tage
Interviews
SENOLOGIE update 2014
Bildgebung
Pathologie, Molekularbiologie, Genetik
Adjuvante Therapie des Mammakarzinoms
Operative Therapie I
Operative Therapie II
Varia I
Varia II
International Diagnostic Course Davos 2014
Prostate Cancer: Update 2014
Interview with Prof. Dr. med. et Dr. h.c. Hedvig Hricak, Memorial Sloan-Kettering Cancer Center, New York
Per Skaane, Oslo, Norway: Tomosynthesis -
Ernst Wyrsch, Davos, CH:
16. Schweizer Onkologiepflege Kongress
Hauptvorträge
St. Gallen EORTC Gastrointestinal Cancer Conference 2014
Session 1: Understanding rectal cancer: Biological basis
Session 2: Staging of rectal cancer – early cancer
Session 3: Surgical treatment of rectal cancer I
Session 4: Combined modality therapy in rectal cancer
Session 5: Surgical treatment of rectal cancer II
Session 6: Issues in combined modality treatment for rectal cancer
Session 7: Rectal cancer with synchronous liver metastases
Session 8: Rectal cancer with synchronous liver metastases II
The 10th ESO colorectal cancer observatory
Keynote II: Effective combinations of targeted therapies for colon cancer based on insights in cross-talk between signaling pathways
The 8th Engadin Prostate Cancer Winter Symposium
1st Session - Chair: J. Hugosson, Sweden and F. Recker, CH
2nd Session - Chair: P. Albertsen, USA and Ch. Iselin, CH
3rd Session - Chair: L. Klotz, Canada and R. Grobholz, Switzerland
4th Session - Chair: M. Graefen, Germany and S. Wyler, Switzerland
5th Session - Chair: P. Hammerer, Germany and T. Sulser, Switzerland
6th Session - Chair: M. Emberton, the U.K. and P. Jichlinsky, Switzerland
7th Session - Chair: M. Emberton, the U.K. and P. Jichlinsky, Switzerland (Kopie)
8th Session - Chair: G. Lümmen, Germany and G. Thalmann, Switzerland
9th Session - Chair: M. Stöckle, Germany and M. Kwiatkowski, Switzerland
IBUS SEMINAR 2014
Friday morning sessions
Friday afternoon sessions
Saturday morning sessions
Saturday afternoon sessions
Livecasts & Kongresskalender
Livecast
Kongresskalender 2020
Drugs oral & i.v., Guidelines, Interaktionen
Orale Krebstherapeutika
orale Wirkstoffe A
orale Wirkstoffe B
Orale Wirkstoffe C
Orale Wirkstoffe D
Orale Wirkstoffe E
Orale Wirkstoffe G
Orale Wirkstoffe H
Orale Wirkstoffe I
Orale Wirkstoffe L
Orale Wirkstoffe Ν
Orale Wirkstoffe O
Orale Wirkstoffe P
Orale Wirkstoffe R
Orale Wirkstoffe S
Orale Wirkstoffe T
Orale Wirkstoffe U
Orale Wirkstoffe V
Orale Wirkstoffe Z
Alle Wirkstoffe
Melden Sie fehlende Wirkstoffe
Acronyme
ALK-Inhibitors
Wirkstoffe A
Wirkstoffe B
Wirkstoffe C
Wirkstoffe D
Wirkstoffe E
Wirkstoffe F
Wirkstoffe G
Wirkstoffe H
Wirkstoffe I
Wirkstoffe K
Wirkstoffe L
Wirkstoffe M
Wirkstoffe N
Wirkstoffe O
Wirkstoffe P
Wirkstoffe Q
Wirkstoffe R
Wirkstoffe S
Wirkstoffe T
Wirkstoffe U
Wirkstoffe V
Wirkstoffe Z
Behandlungsguidelines
Journal of Oncoletter
The Cancer Cell Line Encyclopedia
Texte zur Medizinischen Onkologie aus dem Swiss Medical Forum
Oncologic emergencies
Interaktionsprüfungen
Krebserkrankungen (Entstehung & Verlauf)
Krebserkrankungen B
Krebserkrankungen D
Krebserkrankungen E
Krebserkrankungen G
Krebserkrankungen H
Krebserkrankungen L
Krebserkrankungen M
Krebserkrankungen N
Krebserkrankungen P
Krebserkrankungen S
Wissenschaftlicher Beirat Oncoletter
Nebenwirkungen & Behandlungs- vorschläge
Symptome
Allgemeine Störungen
Fatigue
Fieber/Infektion
Ödeme
Schmerzen
Stimmungsschwankungen
Atmungsorgane
Dyspnoe
Epistaxis/Nasenbluten
Pleuraerguss
Augen
Konjunktivitis
Periorbitale Oedeme
Sehstoerungen
Blut- und Lymphsystem
Anaemie
Lymphopenie
Neutropenie
Thrombozytopenie
Gastrointestinale Störungen
Abdominalschmerz
Diarrhoe
Dyspepsie
Mukositis/Stomatitis
Nausea und Erbrechen
Obstipation
Haut
Aktinische Keratose
Alopezie
Hand-Fuss-Syndrom
Hyperkeratose
Photosensivitätsreaktion
Plattenepithelkarzinom der Haut
Praevention von Pruritus, Rash, Desquamation
Pruritus
Rash, papulopustulöse, follikuläre Exantheme
Seborrhoische Keratose
Sonnenbrand
Trockene Haut
Herz, Gefässe
Arterielle Hypertonie
Blutungen
Herzinsuffizienz
Hitzewallungen
Verminderung der linksventrikulären Auswurfsfraktion (LVEF)
Leber und Galle
Dosierungsempfehlungen oraler TKI/mTor-Inhibitoren bei Leberdysfunktion
Gamma-Glutamyl-Transferase
Muskelskelettsystem
Arthralgien
Knochenschmerzen
Muskelschwaeche
Muskelverhaertungen und Muskelkraempfe
Muskuloskelettale Beschwerden/Schmerzen in den Extremitaeten/Gliederschmerzen
Myalgie/Muskelschmerzen
Rueckenschmerzen
Nervensystem
Dysgeusie
Insomnie
Kopfschmerzen
Neuropathie/Polyneuropathie
Reversible posteriore Leukenzephalopathie
Niere und ableitende Harnwege
Harnwegsinfekt
Stoffwechsel- und Ernährungsstörungen
Amylase-/Lipasewerte
Anorexie
Cholesterol- oder Triglyzeridwerte
Gewichtszunahme
Glucosewerte
Hypokaliämie
Hypokalzämie
Hypophosphatämie
Hypothyreose
Referenzen
Nutzungsbestimmungen
Organisationen
Fachgesellschaften
Info für PatientINNen
Netzwerke
Navigation überspringen
Navigation/Menu
Navigation überspringen
Kongressberichte & Archiv
The 22nd ESMO World Congress on Gastrointestinal Cancer - Virtual Congress
Session I: Cancer of the Pancreas and Biliary Tract
Session II: Hepatocellular Cancer
Session III: Esophageal and Gastric Cancer
Session IV: Gastrointestinal Stromal Tumors (GIST); Neuroendocrine Tumors (NET)
Session V: Molecular Screening; Imaging; Artificial Intelligence
Session VI: Colorectal Cancer I
Session VII: Colorectal Cancer II
Session IX: Rectal Cancer
Virtual Edition of the 25th Annual Congress of the European Hematology Association
Presidential Symposium
Plenary Session I
Plenary Session II
Late-Breaking Oral Session - available fromSaturday June 13 8.30 AM
Oral Sessions
Acute Leukemia
ALL:
AML:
Lymphoma
Aggressive Lymphomas
Hodgkin lymphoma - Clinical
Indolent and mantle-cell non-Hodgkin lymphoma:
Chronic Myeloid Neoplasms
CML clinical
MDS:
MPN (Myelofibrosis & Hypereosinophilic Syndrome)
Chronic Lymphoid Neoplasms
CLL:
Multiple Myeloma
Immunology
CART cells
Immunotherapy:
Stem cell transplantation:
Red & White Cell Disorders
Iron in focus
Sickle cell disease:
Thalassemia:
ITP:
Link to Satellite Session - Live Fri 12 Jun 17:30-18:30
e-Poster Presentations
ASCO20 Virtual Scientific Meeting
Studies presented at press briefings
Pre-Meeting Presentation
Press Briefing May 28
Plenary Session Abstracts
Oral Sessions
Breast Cancer I
Breast Cancer II
Brustkrebs Interviews
CNS Tumours
Developmental Therapeutics I
Developmental Therapeutics II
Gastrointestinal Cancer I
Gastrointestinal Cancer II
Genitourinary Cancer I
Genitourinary Cancer II
Gynecologic Cancer
Gynäkologische Karzinomata - Interviews
Head and Neck Cancer
Hematologic Malignancies I
Hematologic Malignancies II
Hematologic Malignancies III
Lung Cancer I
Lung Cancer II
Skin Cancers
Sarcoma
Pediatric Oncology I
Pediatric Oncology II
SAMO Virtual Workshop on COVID19:
Coronavirus/Brustkrebs
AGO MAMMAKARZINOM - State of the Art Meeting 2020
Keynote-Lecture: Fatima Cardoso
Vormittag 1
Vormittag 2
Nachmittag 1
Nachmittag 2
Interviews im Rahmen einer Kooperation von Oncoletter mit Brustkrebs Deutschland e.v.
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Andreas Schneeweiss, Heidelberg, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Volkmar Müller, Hamburg und Wolfgang Janni, Ulm, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Diana Lüftner Berlin, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Christian Jackisch, Offenbach & Andreas Schneeweiss, Heidelberg, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Bernd Gerber, Rostock zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Volkmar Müller und Ute-Susann Albert, Frankfurt, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Achim Rody, Lübeck, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Achim Wöckel, Würzburg und Christoph Thomssen, Halle zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Michael Lux, Erlangen, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit David Krug, Kiel, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Christoph Thomssen, Halle, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Nina Ditsch, München, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Marc Thill, Frankfurt und Michael Untch, Berlin, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Tanja Fehm, Düsseldorf und Elmar Stickeler, Aachen, zum Thema:
Gespräch mit Kerstin Rhiem, Köln, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Jens Huober, Ulm, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Thorsten Kühn, Esslingen und Jens Uwe Blohmer, Berlin, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Hans H. Kreipe, Hannover, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Ingo Bauerfeind, Landshut und Nina Ditsch, München, zum Thema:
Ten Years of ETOP
2nd Zurich Brain Metastasis Symposium
Experimental Studies
Keynote Lectures
Updates on Therapeutic Approaches
Brain Metastasis: Disease Updates
Controversies & Hot Topics in the Diagnosis and Management of CNS Metastasis
SABCS - 42nd Annual San Antonio Breast Cancer Symposium
Press Conferences
Wednesday, Dec. 11
Thursday, Dec. 12
Friday, Dec. 13
General Sessions 1-6
GENERAL SESSION 1:
GENERAL SESSION 2:
GENERAL SESSION 3:
GENERAL SESSION 4:
GENERAL SESSION 5:
GENERAL SESSION 6:
Interviews - Breast Cancer
HER 2-positiver, metastasierter Brustkrebs: HER2CLIMB Studie mit Tucatinib
HER 2-positiver, metastasierter Brustkrebs: DESTINY-Breast01 Studie mit Trastuzumab Deruxtecan
HER 2-positiver Brustkrebs adjuvant: APHINITY Studie, 2. Zwischenanalyse
HER 2-positiver Brustkrebs adjuvant: ATEMPT Studie T-DM1 gegen Paclitaxel plus Trastuzumab
Einsatz von Capecitabine Neo/Adjuvant
GEPARX Studie: Denosumab im Vergleich zu zwei Nab-Paclitaxel Schemata - neoadjuvant
Immuncheckpoint-Inhibitoren: Durvalumab beim metastasierten BC und Pembrolizumab neoadjuvant und adjuvant bei TNBC
pCR bei neoadjuvanter Therapie mit Atezolizumab beim TNBC?
Neues zu CDK4/6 Inhibitoren (HR+ & HER2-)
Wenn der Brust-Tumor weg ist nach neoadjuvanter Therapie: Muss noch operiert werden?
Teil- oder Ganzbrustbestrahlung nach Brust erhaltender Therapie. Was für wen?
Schweizer Expertenrunde mit einigen Highlights vom SABCS:
Round Table mit Brustkrebs Deutschland e.V.
61st ASH Annual Meeting and Exposition
Highlights of the Conference: Statements & Opinions
ALL
Multiples Myelom
Multiples Myelom
Lymphome
Press Briefings
Saturday, December 7:
Saturday, December 7:
Saturday, December 7:
Sunday, December 8:
Monday, December 9 (embargoed until Tuesday 7:30 AM EST):
Late Breaking Abstract Session
Acute Lymphoblastic Leukemia (excluding Transplantation)
Therapeutic Strategies
Novel Therapies
Clinical Studies - Choice of Poster-Abstracts with Asparaginase
CAR T Cells--Refining the Approach
Chemo Immuno and Targets--Improving Combinations in ALL
Acute Myeloid Leukemia (excluding Transplantation)
Clinical Studies: Non-Intensive Therapy
Intensive Upfront Chemotherapy
Treatment of Relapsed/Refractory Disease
Induction and Post-Remission Therapy
New Treatment Strategies
Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs
Novel Targets and Combinations
Chronic Myeloid Leukemia: Therapy
Predictors of TKI Discontinuation and TFR Outcomes
Clinical Trials and Outcomes
Response Monitoring and Prognosis
Myeloproliferative Syndromes
Emerging and Novel Targeted Therapies
JAK Inhibitors and Combination Therapies
Myelodysplastic Syndromes
Combination Therapies
Targeting Gene Mutations in MDS
Lower-Risk MDS and CMML
SAKK POSTER
Myeloma: Therapy, excluding Transplantation
New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias
Novelty in CAR T in Relapsed/Refractory Multiple Myeloma
Therapeutics Questions in Newly Diagnosed Myeloma
Improving the Outcomes of Newly Diagnosed Multiple Myeloma
Novel Therapy for Relapsed Myeloma
CLL (excluding Transplantation)
First Line Treatment
Combination and Novel Treatment
BTK Inhibitors and CAR T Cells in CLL
Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
Follicular Lymphoma: Biomarkers and Clinical Trials
Clinical Trials in Waldestrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas
Mantle Cell Lymphoma: Frontline and Relapsed Therapies
Hodgkin Lymphoma and T/NK Cell Lymphoma
Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma
Immunotherapy Approaches in Hodgkin Lymphoma
Novel Therapies in Peripheral T-cell Lymphomas
Aggressive Lymphoma (DLBC and Other Aggressive B-Cell Non-Hodgkin Lymphomas
Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy
Results from Prospective Clinical Trials: Results from CAR T-Cell Trials
Novel Therapies in Relapsed/Refractory Disease
Results from Retrospective/Observational Studies: Population-Based Outcomes
Results from Retrospective/Observational Studies: Prognostic Markers
Results from Retrospective/Observational Studies: Cellular Therapies
Immunotherapies
Immunotherapies I
Immunotherapies II
Gene Therapy and Transfer
Advancing CAR T Cells: New Biology and Therapeutic Applications
Gene Therapies for Non-Malignant Disorders
CAR-T-Zell Therapie in der Schweiz
Archiv 2019
8. Interdisziplinäres Prostatakarzinom-Symposium 2019
I Grundlagen und Früherkennung
II Lokoregionäre Therapie des Prostatakarzinoms
III Aspekte der Systemtherapie des Prostatakarzinoms
Cancer Academy – Immuntherapie
Jahrestagung 2019 von DGHO, OeGHO, SGMO und SGH+SSH
Pressekonferenz
OnkoZentrum Zürich - Patientenforum 2019
ESMO 2019
Press Briefings
Opening Press Conference
Lung and gynaecological cancers
Breast cancer
Gastrointestinal and genitourinary cancers
SAKK Studien am ESMO 2019
Brustkrebs
Gastrointestinal Cancers
Metastatic Colorectal Cancer (mCRC)
More from BEACON CRC & TAILOR
Metastatic Gastric, Pancreatic & Biliary Cancer
Lung Cancer, Mesothelioma & Head and Neck Cancer
Melanoma
Ovarialkarzinom
Cancer Academy - Kopf-Hals-Tumore
IASLC 2019 World Conference on Lung Cancer (#WCLC19)
Interviews
Press Briefings
Saturday, September 7th Press Briefing
Sunday, Sept. 8th Press Briefing
Monday, Sept 9th (Presidential Symposium Press Briefing)
Tuesday, Sept 10th Press Briefing
4th Zurich Immuno-Oncology Symposium
Keynote Address
Therapeutic Developments I
Therapeutic Developments II
Challenges in Patient Management
Challenges in Optimizing Treatment
Cell-based Therapies
ESMO World Congress on Gastrointestinal Cancer
Press Conferences (News being made available according embargo rules)
Wednesday, 3 July - Opening Press Conference
Thursday, 4 July - Key studies of the day
Friday, 5 July - Key studies of the day
Session II: Cancer of the Pancreas and Biliary Tract
Presentation of Selected GI Cancer Abstracts
Presentation of Selected Rectal Cancer Abstracts
Session VII: Gastric Cancer - Presentation of Selected Abstracts
Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 1
Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 2
Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 1
Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 2
Session XVI: Hepatocellular Cancer - Presentation of Selected Abstracts
Session XX: Colorectal Cancer (Part I) - Presentation of Selected Abstracts & Comments Roger von Moos and Thomas Winder
Second Zurich Lung Cancer Symposium
Lung Cancer Screening and Approach to Small Lesions
Molecular Pathology of Lung Cancer
Development in Stage III NSCLC Disease
The Improvement of Survival in Metastatic NSCLC
The Importance of Clinical Trials
Approach to Oligometastatic Disease
15th International Conference on Malignant Lymphoma (ICML)
Introductory Press Conference
PLENARY SESSION
MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD?
HOW TO APPROACH CLL IN CLINICAL PRACTICE
THE MODERN APPROACH TO MANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA
PET IMAGING
PEDIATRIC LYMPHOMA
RESULTS FROM SINGLE AGENT TRIALS
ONGOING TRIALS
DLBCL: CLINICAL DATA
CLL
TREATMENT WITH NOVEL ANTIBODIES
T-CELL LYMPHOMAS
CLL AND MORE
CHEMOTHERAPY-FREE STRATEGIES
NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS
HIGH RISK LARGE B-CELL LYMPHOMAS
LYMPHOMA PATHOLOGY
HODGKIN LYMPHOMA
FOLLICULAR LYMPHOMA
EXTRANODAL LYMPHOMAS
NEW DATA ON T-CELL AND OTHER LYMPHOMAS
ADVANCES IN CAR T-CELL TREATMENT
NEW DRUG COMBINATIONS
INDOLENT NON-FOLLICULAR LYMPHOMA
24th Congress of EHA
Presidential Symposium
Late-breaking oral presentations (6 best abstracts)
Important presentations at Press Briefings
Friday, June 14, 2019
Saturday, June 15, 2019
Indolent and mantle-cell non-Hodgkin Lymphoma - clinical
Aggressive lymphomas - New agents
Aggressive lymphomas - First line, combination therapy and real-life data - Aggressive non-Hodgkin lymphoma
Hodgkin lymphoma - clinical
Novel agents and therapies for CLL
New stratification and treatment approaches in ALL - including CAR T Cell therapy
Advances in the management of thalassemia
Immunotherapy in relapsed/refractory multiple myeloma
Novel strategies in multiple myeloma
Novel agents for newly diagnosed plasma cell dyscrasias
Myeloma and other monoclonal gammopathies - Clinical
New therapies in AML
Gene therapy, cellular immunotherapy and vaccination - Biology & translational research
Gene therapy, cellular immunotherapy and vaccination - Clinical
Update on clinical trials in MPN
New agents in MPN
Annual Meeting of the American Society of Clinical Oncology 2019
Press Briefings
May 15 Presscast
Press Briefing Saturday June 1:
Press Briefing Sunday June 2:
Press Briefing Monday June 3:
Breast Cancer
Breast Cancer News Interviews
Breast Cancer News Aufzeichnung Live-Stream
Oral & Poster Presentations
Colon Cancer
Oral Presentations
Poster Presentations
Other gastrointestinal Cancer
Oral Presentations
Poster Presentations
Other Gynaecologic Cancers
Head & Neck Cancers
Oral Presentations
Poster Presentations
Lung Cancer
Hauttumore
Urogenital Cancers
Oral Presentations
Poster Presentations
Hematology
Multiple Myeloma & Myelofibrosis
Lymphoma & CLL
ALL
Senologie Update 2019
Teil 1:
Teil 2:
Teil 3:
Teil 4:
ELCC 2019 - European Lung Cancer Congress | ESMO 10-13 April 2019 Geneva, Switzerland
BCC2019
Opening and Award Ceremony:
Session 1: News since St.Gallen 2017
Session 2: Biology of Breast Cancer I: Risk stratification
Session 3: Biology of breast cancer II: Prediction of response
Session 4: Risk stratification and prevention in ductal in situ carcinoma
Special lecture I and II
Session 5: New pathways with potential impact in the treatment of early breast cancer
Session 6: Treatment tailoring according to pathology and biology
Session 7: Surgery of early breast cancer
Session 8: Radiotherapy of early breast cancer
Special lecture III
Session 9: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit I
Session 10: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit II
GenomicHealth interactive satellite symposium in conjunction with the 16th St Gallen International Breast Cancer Conference
Nanostring Satellite Symposium: Recent Breakthroughs for HR+/HER2- Early Breast Cancer Patients:
Interviews (in German): Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
Three SAKK Posters
45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Interviews
Presidential Symposium
GS2-2 - IMPROVED SURVIVAL OF AML- AND MDS-PATIENTS AFTER TREOSULFAN-BASED COMPARED TO REDUCED‑INTENSITY BUSULFAN-BASED CONDITIONING-REGIMEN FOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION: FINAL RESULTS OF A PROSPECTIVE RANDOMISED PHASE-III-TRIAL
GS2-3 - GRAFT-VERSUS-LEUKEMIA EFFECT AFTER HAPLO-IDENTICAL STEM-CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN AML- NO ASSOCIATION WITH GRAFT-VERSUS-HOST-DISEASE: A STUDY OF THE ACUTE LEUKEMIA WORKING PARTY OF EBMT
GS2-4 - SEQUENTIAL CD19- AND CD22-CART CELL THERAPIES FOR RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 10-MONTH MEDIAN FOLLOW-UP
GS2-5 - ALLOGENEIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS VERSUS MATCHED OR MISMATCHED 9/10 UNRELATED DONORS IN ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION
GS2-6 - LOW-DOSE INFUSIONS OF CD45RA DEPLETED DONOR LYMPHOCYTES AFTER TCR ALPHA/BETA-DEPLETED TRANSPLANTATION IN PATIENTS WITH NON-MALIGNANT DISORDERS
GS2-7 - CELL-MEDIATED IMMUNOGENICITY OF THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) IN ADULT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED ZOE-HSCT CLINICAL TRIAL
Oral Session 9: Late-breaking abstracts
OS9-1 - COMPARABLE OUTCOME AFTER 10/10 AND 9/10 HLA-MATCHED UNRELATED DONOR STEM CELL TRANSPLANTATION (HSCT) USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) FOR GVHD PROPHYLAXIS, ON BEHALF OF THE ALWP-EBMT.
OS9-2 - MYELOABLATIVE CONDITIONING FOR FIRST ALLOGENEIC HSCT IN PEDIATRIC ALL: FTBI OR CHEMOTHERAPY? - AN UPDATE OF THE RETROSPECTIVE MULTICENTER EBMT-PDWP STUDY
OS9-3 - THE DETECTION OF THE SOLUBLE EBV ZEBRA PROTEIN AS A NEW PREDICTIVE BIOMARKER FOR PTLD
OS9-4 - EFFECTIVE CANCER IMMUNOTHERAPY WITH ERBB2-CAR-ENGINEERED CYTOKINE-INDUCED KILLER (CIK) CELLS IN HIGH-RISK SOFT TISSUE SARCOMAS
OS9-5 - GENESIS - A PHASE III RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, EVALUATING SAFETY AND EFFICACY OF BL-8040 AND G-CSF IN MOBILIZATION OF HCS´S FOR AUTOLOGOUS TRANSPLANTATION-MULTIPLE MYELOMA
OS9-6 - REAL LIFE EXPERIENCE IN THE TREATMENT OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT ALL PATIENTS USING COMMERCIALLY AVAILABLE CAR-T-CELLS
How Do I... manufacture T cells for cellular therapies
HDI1-1 - Manufacturing of virus-specific T cells at an academic center
HDI1-2 - CAR T manufacturing in an academic setting
HDI1-3 - Low-dose memory T cell DLI for infection prophylaxis
How Do I... manage patients after CAR T-cell therapy.
HDI8-1 - Lymphoma, CLL and ALL
HDI8-2 - Myeloma patients
HDI8-3 - From a nurse's perspective
New developments in the field of CAR cell therapy
P2-1 - State of the art for ex-vivo manufactured autologous CAR T-cells
P2-2 - Simultaneous targeting of CD19 and CD22 with a bicistronic CAR - preliminary results of the AMELIA study
P2-3 - Off-the-shelf CAR NK cells for the treatment of hematologic malignancies
P2-4 - CAR T-cells against solid tumors: TRUCKs on the road
AGO MAMMAKARZINOM - State of the Art Meeting 2019
Vormittag 1
Vormittag 2
Nachmittag 1
Nachmittag 2
Interviews: Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
First Zürich Precision Oncology Symposium
Speakers
Molecular Testing and Molecular Tumor Board
Keynote address
Precision Oncology for Solid Tumors 1/Ongoing Research Activities 1
Precision Oncology for Solid Tumors 2
Precision Oncology for Hematologic Malignancies
Precision Oncology for Solid Tumors 2/Ongoing Research Activities 2
The Gastrointestinal Cancers Symposium 2019
ASSOC.PROF. PD DR. GERALD PRAGER, WIEN: Cancers of the Esophagus and Stomach - the Highlights
General Session 1:
General Session 2:
Rapid Abstract Session A:
Breakout Session: Palliation of Esophago-Gastric Malignancies
Oral Abstract Session A:
General Session 3:
Poster Walks:
Rapid Abstract Session B:
Breakout Session: Novel Innovations in Pancreatic and Hepatobiliary Malignancies
Welcome and General Session 4:
General Session 5:
Keynote Lecture: Kelly McMasters
ASSOC.PROF. PD DR. GERALD PRAGER, WIEN: Cancers of the Pancreas - the Highlights
Oral Abstract Session B:
General Session 6:
Poster Walks:
liposomal irinotecan (nal-IRI) 2nd line & neoadjuvant
PD DR. MED. DOMINIK MODEST, MÜNCHEN - Colon Cancer - Personal Highlights
Rapid Abstract Session C:
Welcome and Keynote Lecture:
Breakout Session: The Latest Updates on HIPEC for Gastrointestinal Cancers
General Session 7:
Oral Abstract Session C:
Poster Walks:
General Session 8:
General Session 9:
POSTER SESSIONS A,B,C
Trials in Progress Poster Session A, B, C
Presentations with trifluridine/tipiracil (FTD/TPI) at the Gastrointestinal Cancers Symposium
Archiv 2018
SABCS - 41st Annual San Antonio Breast Cancer Symposium
Press Conferences
Wednesday, Dec. 5, Press Conference 1
Wednesday, Dec. 5, Press Conference 2
Thursday, Dec. 6 Press Conference
Friday, Dec. 7 Press Conference
Schweizer Poster am SABCS
Interviews - Breast Cancer
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Achim Rody, Lübeck
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle/Saale
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Priv.-Doz. Dr. med. Hans-Christian Kolberg in Bottrop
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Thorsten Kühn, Esslingen
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Wilhelm Braun, München
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Sibylle Loibl, Frankfurt
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Michael Untch, Berlin-Buch
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. Rachel Würstlein, München
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Jörg Schilling, Berlin
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Priv.-Doz. Dr. med. Hans-Christian Kolberg, Bottrop
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Lothar Müller, Onkologie Unterems
Schweizer Expertenrunde mit einigen Highlights vom SABCS:
Round Table mit Brustkrebs Deutschland e.V.
General Sessions
GENERAL SESSION 1:
GENERAL SESSION 2:
GENERAL SESSION 3:
GENERAL SESSION 4:
GENERAL SESSION 5:
GENERAL SESSION 6:
American Society of Hematology (ASH) 60th Annual Meeting and Exposition
Statements & Opinions from some Highlights of the Conference
PD Dr. med. Nicolas Bonadies, Bern
Prof. Dr. med. Christoph Driessen, St. Gallen
Prof. Dr. med. Christoph Renner, Zürich
Press Briefings
Saturday December 1
Sunday December 2
Monday December 3
Late-Breaking Abstracts Session
Myeloma: Therapy and upfront autologous Transplantation
Novel Antibody Combinations in Myeloma
Novel Targeted Combinations in Myeloma
Antibodies and Targeted Therapies
Novel Proteasome Inhibitors
Immunotherapies in Plasma Cell Disorders
Immunotherapy
Upfront Autologous Transplantation
Choice of Myeloma Posters
AML
Acute Myeloid Leukemia - Clinical Studies
Acute Myeloid Leukemia - Commercially Available Therapy, excluding Transplantation:
Acute Myeloid Leukemia - Novel Therapy, excluding Transplantation
Lymphoma
Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies
Acute Lymphoblastic Leukemia: Clinical Studies & Therapy Excluding Transplantations
Improving Outcomes with Cellular Therapy
Improving Frontline Therapy in ALL
Chimeric Antigen Receptor T-cell therapy in ALL: What Is Next?
Targeted Therapy in ALL: Immunotherapy and Beyond
CLL: Therapy, excluding Transplantation:
Measurable Residual Disease in CLL: Moving Towards a Cure
Cellular Therapy and Immunomodulation in CLL
Advances in CLL Using Novel Combination Therapy
Chronic Myeloid Leukemia: Therapy
Epidemiology, Prognosis, and Real Life Care
First Line Trials and Prognostic Factors of Treatment-Free Remission
TFR Failure, Resistance, and New Drug Development
Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics, Prognosis and Prediction
Novel Therapeutics I
Novel Therapeutics II
Prognosis and Prediction
Scientific, medical, clinical, relevant “asparaginase” related Presentations
Health Services & Outcome Research—Malignant Diseases
Clinical Trials for Hemophilia and Using CAR T Cells
Thalassemia and Globin Gene Regulation
Cancer Academy: Sarkome, Früherkennung, Diagnose und Behandlung
ESMO 2018 Congress
Press Briefings
Breast Cancer
Ovarian Cancer
Prostate & Kidney Cancers
Head & Neck Cancer
All ESMO 2018 Press Releases
Interviews
Interviews - Breast Cancer
Statement Summary GIT-Cancers
Statements Colorectal Cancer
Statements Gastric Cancer
Statements Lung Cancer
Statement Renal Cell Carcinoma
Links to selected presentations and abstracts
Presidential Sessions
Selection of Posters
Cancer Academy - Blut- und Lymphdrüsenkrebs
Comprehensive Cancer Center Zürich: Third Zurich Immuno-Oncology Symposium
Keynote address
Clinical results, patient cases and future developments I
Clinical results, patient cases and future developments II
Clinical results, patient cases and future developments III
Developments in immunotherapy
20th World Congress on Gastrointestinal Cancer (WCGIC 2018)
Session I: Welcome with Selected Abstracts
Session II: Cancer of the Pancreas and Biliary Tract - Selected Abstracts
Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer
Pancreatic Cancer: Poster Session
Session VII: Gastric Cancer: Presentation of selected abstracts
Session VIII: Diseases and Cancers of the Liver: Presentation of a selected abstract
Session XI: Presentation of Selected Abstracts: Colorectal Cancer
Session XX: Colorectal Cancer: Presentation of selected abstracts
23rd Congress of EHA
Presidential Symposium
Plenary Session Abstracts
Press Briefings
Press Briefing Day 1
Press Briefing Day 2
Important AML Presentations
IDHm and BCL2 inhibitors in AML
One AML Poster
Important CLL Presentations
Important Multiple Myeloma Presentations
Advances in front-line treatment of newly diagnosed multiple myeloma
New therapeutic strategies to improve the outcome of relapsed/refractory plasma cell disorders
Multiple Myeloma Poster Presentations
One Multiple Myeloma Late Breaking Abstract
Important Lymphoma Presentations
Thalassemia (2 Presentations) & MDS (1 Presentation)
Annual Meeting of the American Society of Clinical Oncology 2018
Highlights of the day
Sunday
Monday
Tuesday
Press Briefings
May 16 Presscast
Press Briefing 1 Friday June 1:
Press Briefing 2 Saturday June 2:
Press Briefing 3 Sunday June 3:
Press Briefing 4 Monday June 4:
Breast Cancer
Breast Cancer News from Oral Sessions
Breast Cancer News from Poster Sessions
Breast Cancer News Interviews
Colon Cancer
Colon Cancer News from Poster Sessions
Lung Cancer
Lung Cancer News from oral sessions
Lymphoma
Lymphoma News Oral Sessions
Lymphoma News Poster Sessions
Merkel-Cell Carcinoma
Myeloid Diseases
Myeloid Diseases News from Oral Sessions
Myeloid Diseases News from Poster Sessions
Other Hematologic Malignancies
Pancreatic Cancer
Pancreatic Cancer News from Oral Sessions
Pancreatic Cancer News from Poster Sessions
Urologic Cancers
Renal Cancer
ESMO Preceptorship on Colorectal Cancer 2018
SENOLOGIE update 2018
Prophylaktische Mastektomie - Moderation: M. Knauer, St. Gallen
Psychosoziale Konsequenzen des Mammakarzinoms - Moderation: E. Sarasin, Zürich
Update Systemtherapie - Moderation: U. Breitenstein, Zürich
Varia - Moderation: E. Saurenmann, Zürich
Cancer Academy - Darmkrebs
AACR Annual Meeting 2018, April 14-18,
Highlights presented at the Press Conference Sunday, April 15
Highlights presented at the Press Conference Monday, April 16
Highlights presented at the Press Conference Tuesday, April 17
ELCC 2018 (European Lung Cancer Congress)
Highlights - Press Releases
Interviews
Conference Highlights
Interviews in Cooperation with the Video Journal of Oncology - Part 1
SAKK 16/14 – Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
11th European Breast Cancer Conference (EBCC-11)
Press conferences
Important News
Interviews
PD Dr. med. Christian Kolberg, Bottrop
Prof. Dr. med. Thorsten Kühn, Esslingen
Prof. Dr. med. Nadia Harbeck, München
St. Gallen International Gastrointestinal Cancer Conference Primary Therapy of Early GI Cancers -
Session 1: Oesophago-Gastric Cancer: One Disease or Separate Entities?
Session 2: Treatment of Oesophago-Gastric Cancer: Setting the Stage – Who Benefits from Multimodal Therapy
Session 3: Treatment Modalities for Oesophago-Gastric Cancer
Session 4: Special situation I: Signet Ring Cell Cancer
Keynote: Hereditary Gastric Cancer
New Therapy Options by metastatic Colorectal Cancer
Session 5: Special situation II: Limits of Curative Approaches to Metastatic Oesophago-Gastric Cancer
Session 6: Ready for Practice?
EORTC Gastrointestinal Tract Cancer Group:
Cancer Academy - Prostatakrebs
Promoting Self-efficacy with Digital Tools
Welcome (German)
Promoting patients’ self-efficacy: How can it be successful? (German)
United Kingdom’s perspective on the use of digital solutions to improve cancer patients’ self-efficacy
Presentation of selected digital and patient-oriented applications
Consilium: Patient-centered communication for improved self-efficacy and quality of life
STREAM – Ein online Programm zur Unterstützung bei Belastung während einer Krebserkrankung
Symptom Navi: Förderung des Selbstmanagements von Symptomen bei Krebs
Entspannung und Achtsamkeit für Krebspatienten mit Hilfe einer App (CanRelax)
FertiOnco – an online approach to facilitate decision making in young female cancer patients regarding fertility preservation
The use of patient-reported outcomes to improve outcomes and quality in cancer care
Digital solutions for cancer patients: reach, (cost-) effectiveness and implementation
Discussion and Closing remarks (German)
Gastrointestinal Cancers Symposium Jan 18-20, 2018 San Francisco, California
Cancers of the Esophagus and Stomach
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Videostatements
Studies presented in oral sessions
Posters
Posters
Cancers of the Colon, Rectum, and Anus
Videostatement
Studies presented in oral sessions
Choice of Posters
Archiv 2017
59th ASH Annual Meeting and Exposition
Late-Breaking Abstracts Session
AML
Oral Sessions
Multiple Myeloma
Oral Sessions
Choice of Posters
Lymphoma
Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
Hodgkin Lymphoma and T/NK Cell Lymphoma
CLL: Therapy, excluding Transplantation:
Press Conferences
Novel Approaches to Hemophilia and Venous Thromboembolism Care
Engineering Solutions to Treat Inherited Blood Disorders
Enhancing Care in Hematologic Malignancies through Targeted Therapies
Driving Outcomes in Lymphoma, Myeloma with CAR T-Cell Therapies
Late-Breaking Abstracts
Interviews
Statement Christian Taverna, Münsterlingen
Statement Thorsten Zenz, Zürich
40th Annual San Antonio Breast Cancer Symposium (SABCS)
General Sessions
GENERAL SESSION 1:
GENERAL SESSION 2:
GENERAL SESSION 3:
GENERAL SESSION 4:
GENERAL SESSION 5:
GENERAL SESSION 6:
Press Conferences
Wednesday December 6 @ 7:15 a.m.
Wednesday December 6 @ 12:15 p.m
Thursday December 7 @ 7:30 am
Friday December 8 @ 7:30 am
Interviews & Brustkrebs Deutschland Round Table & SAKK Roundtable
Roundtable Brustkrebs Deutschland
Roundtable mit Experten aus der Schweiz
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Peyman Hadji, Marburg
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Peyman Hadji, Marburg
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin (Kopie)
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Stefan Buchholz, Regensburg
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Thorsten Kühn, Esslingen
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Dr. phil. Ute Berndt, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr.med. Michael Untch, Berlin-Buch
Cancer Academy – Hirntumoren
7. Interdisziplinäres Prostatakarzinomsymposium
Grundlagen
Lokalisiertes & oligometastatisches Prostatakarzinom
Systemtherapien Prostatakarzinom
Advanced Breast Cancer 4th ESO-ESMO International Consensus Conference
Cancer Academy – Brustkrebs
ESMO 2017 Congress
Breast Cancer Highlights
Neoadjuvante Therapie bei luminalem, triple negativem oder HER2 positivem Brustkrebs
Luminaler Brustkrebs - wer braucht Chemotherapie?
CDK4-6 Inhibitoren beim metastasierten Brustkrebs
Abstract LBA10_PR ‘Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)’
Abstract 1472P_PR ‘Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients’
Gastrointestinal Carcinoma Highlights
Colorectal Cancer
Gastric Cancer
Head & Neck Cancer Highlights
PD Dr. med. Sacha Rothschild comments Head&Neck Cancer Studies
Abstract LBA45_PR ‘Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial’
1065P - 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis
1. First line Cetuximab and Cisplatin with or without Paclitaxel/2. The observational ENCORE study: Cetuximab + platinum-based therapy
Lung Cancer Highlights
Prof. Martin Reck
PD Dr. AlessandraCurioni-Fontecedro
PD Dr. AlessandraCurioni-Fontecedro
Prof. Dr. med.Solange Peters
Alectinib: ALEX and ALUR trials show CNS benefit in NSCLC
Melanoma & Merkel Cell Carcinoma Highlights
Prof. Dr. med. Reinhard Dummer, Zurich
Prof. Dr. med. Olivier Michielin, Lausanne
Ovarian Cancer Highlights
Urogenital Cancer Highlights
Richard Cathomas, Chur, comments on the urogenital Carcinoma Highlights
Abstract LBA37_PR – ‘Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): mature results from the phase 3 KEYNOTE-045 trial’
Late breaking news
Opening Press Conference
LBA Press Conference: Lung cancer
Press Conference: Facing the challenges of life after cancer
LBA Press Conference: Breast cancer, Gynaecological cancers, Genito-urinary cancers
LBA Press Conference: Melanoma cancer
Wrap-Up press conference/Best of ESMO2017
Cancer Center Zürich Second - Zurich Immuno-Oncology Symposium
Welcome
Essentials of tumour immunology and immunotherapies
Clinical results, patient cases and future developments I
Clinical results, patient cases and future developments II
Clinical results, patient cases and future developments III
Management of toxicities
ESMO 19th World Congress on Gastrointestinal Cancer
Cancer of the Pancreas
Session II: Cancer of the Pancreas & bile Ducts
Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology
Optimizing the Continuum of Care for Patients with Pancreatic Cancer: A Case Study-Based Debate
Interview mit Prof. Gerald Prager, Wien
Colon Cancer Highlights
Session XIX: Colorectal Cancer
Prof. Dr. med. Bernhard Pestalozzi, UniversitätsSpital Zürich:
Die besonderen Bedürfnisse von Kindern und Jugendlichen mit Krebs
14 The International Conference on Malignant Lymphoma (ICML)
Interviews & Introductory Press Conference
Introductory Press Conference
Lymphoma Therapy
Oncoletter Interviews in cooperation with VJHEMONC
Satellite Symposia
THE FIRST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE
CHEMOTHERAPY IN INDOLENT LYMPHOMA - DYING OR WELL ALIVE?
ASCO Annual Meeting 2017
ASCO Press Conferences
ASCO Annual Meeting 2017 Presscast May 17
ASCO Annual Meeting 2017 Presscast June 2
ASCO Annual Meeting 2017 Presscast June 3 Part 1
ASCO Annual Meeting 2017 Presscast June 3 Part 2
ASCO Annual Meeting 2017 Presscast June 4
ASCO Annual Meeting 2017 Presscast June 5
Online-Programm verbessert die Lebensqualität von Krebspatienten
Highlights Mammakarzinom
Brustkrebs Deutschland: Experten-Roundtable vom ASCO Annual Meeting 2017
HER2-positiver, primär metastasierter Brustkrebs
HER2-positiver metastasierter Brustkrebs
PARP-Inhibitoren bei Brustkrebs
Abemaciclib bei Brustkrebs-Hirnmetastasen
HER2-positiver, primär metastasierter Brustkrebs
Scalp-Cooling - Chemo ohne Haarverlust?
CDK 4-6 Inhibitoren: Palbociclib, Ribociclib, Abemaciclib
Ergebnisse der Aphinity-Studie für HER 2 neu-positiven Brustkrebs adjuvant
Stellungnahme zur Relevanz von Studienendpunkten und deren Akzeptanz am runden Tisch: Wir alle müssen umdenken!
Finale Ergebnisse der PlanB-Studie für klinische Hochrisikopatientinnen bzw. mit mittlerem bis hohem Risiko nach Genexpressionstest
Short-HER-Studie:Sind 9 Wochen Trastuzumab nicht schlechter als 1 Jahr?
I-Spy 2-Studie: Immuntherapie mit Pembrolizumab plus Standard neoadjuvante Therapie für Hochrisikopatientinnen
Highlights Ovarialkarzinom
LION Studie: Rolle der Lymphknotenentfernung bei Erstoperation des Eierstockkrebs
DESKTOP 3 Studie: Erneute OP beim Eierstockkrebs Rezidiv
Immuntherapie bei Vulva-, Zervix- und Ovarialkarzinom: gibt es schon Einsatzmöglichkeit?
PARP-Inhibitoren beim Eierstockkrebs: welcher, wann und wie lange?
Head & Neck Cancer Highlights
Highlights Head&Neck
Statements Sacha Rothschild, Jean Bourhis & Marco Merlano
Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)
Highlights Gastrointestinaltumoren
Upper GIT
Colon Cancer
Pancreatic Cancer
Haematologic Malignancies
ELCC 2017 Genf
Cancer Academy – Lungenkrebs: Früherkennung, Diagnose und Behandlung
SENOLOGIE update 2017
Radiologie - Moderation: F. Dammann, Zürich
Genetik - Moderation: R. Morant, Rapperswil
Qualitätssicherung in der Senologie - Moderation: C. Rageth, Zürich
Operative Therapie - Moderation: C. Tausch, Zürich
Das metastasierte Mammakarzionom - Moderation: A. Müller, Winterthur
Varia - Moderation: D. Fink, Zürich
15th St.Gallen International Breast Cancer Conference
Symposium Thoracic Oncology – Guidelines and Beyond
Screening
Inquiring the molecular tumor characteristics
Shanghai meets Zürich
Treatment options in localized NSCLC
Multimodality approaches in rare thoracic tumors
Metastatic disease
Archiv 2016
Das elektronische Patientendossier: das Genfer Beispiel der Integration eines Spitals in eine Referenzgemeinschaft
IASLC 17TH WORLD CONFERENCE ON LUNG CANCER
Fachpressemitteilungen
Lungenkrebs-Weltkongress in Wien: Aktive Prävention, akkurate Diagnostik, aktuelle Fortschritte in der Behandlung
Mutations-Diagnostik setzt sich bei Lungenkrebs durch
Mikro-RNA zur Prognosebestimmung bei Mesotheliom-Erkrankungen
Therapeutische Impfung gegen Lungenkrebs:
Zweite Therapiechance für Lungenkarzinompatienten
58th Annual Meeting of the American Society of Hematology
PRESS CONFERENCES
Developing Novel Therapies and Unique Delivery Methods to Improve Treatment for Bleeding Crises, Leukemia
Revolutionizing Sickle Cell Disease Care in the United States and Abroad
Improved Outcomes in Leukemia, Trauma Settings with Personalized Medicine Approaches
Choice of ASH presentations
616: Acute Myeloid Leukemia
Lymphoma
642. CLL
653. Myeloma
637. Myelodysplastic Syndromes
904. Outcomes Research
112. Thalassemia and Globin Gene Regulation
Interviews Best of ASH (Multiples Myelom, Lymphome)
Zürich, 25. November 2016: 6. Treffen von Krebspatientinnen und -patienten
ESMO-Congress, Oct 07-11, 2016 - Copenhagen, Denmark
Press Conferences
Friday 7 October - Opening Press Conference
Saturday 8 October Press Conference 1: Late Breaking Trials
Sunday 9 October Press Conference 2: Late Breaking Trials
Monday 10 October Press Conference 3: Late Breaking Trials
More Highlights
Metastatic Colorectal Cancer
Cancer Center Zürich First Zurich Immuno-Oncology Symposium
Essentials of tumour immunology and immunotherapies
Clinical results, patient cases and future developments I
Clinical results, patient cases and future developments II
Clinical results, patient cases and future developments III
Management of toxicities
Radiotherapy
Das elektronische Patientendossier als zentrales Instrument der interprofessionellen Zusammenarbeit in integrierten Versorgungsorganisationen
WCGIC - 18th World Congress on Gastrointestinal Cancer
Metastatic & non-metastatic Colorectal Cancer
Statements Ulrich Güller, Andreas Wicki, Thomas Winder
ESMO PRESS RELEASES
Regorafenib shows significant survival gains in refractory liver cancer
Anti-interleukin-1 alpha antibody MABp1 improves outcomes significantly over placebo
Chemoradiotherapy after surgery for gastric cancer shows similar outcomes to post-operative chemotherapy.
Anti-PD-L1 immunotherapy shows response in microsatellite-stable metastatic colorectal cancer in combination with MEK inhibition
Satellite Symposia
Developing a continuum of care for patients with metastatic pancreatic cancer: A case study-based debate
mCRC Myth-Busters reloaded: More facts for optimal patient benefit!
Zürich, 1. Juli 2016: 5. Treffen von Krebspatientinnen und -patienten
Bern, Donnerstag 29. Juni 2016: Den Patienten integrieren - ein Symposium der Nationale Strategie gegen Krebs:
The 21st EHA Annual Congress
EHA Highlights presented at the press conference
Friday June 10
Saturday June 11
36. Jahrestagung Deutsche Gesellschaft für Senologie 25.–28. Mai 2016, Dresden
Das Wichtigste vom Tage
Lunchsymposium: Genomic Health – Oncotype DX
Interviews
SENOLOGIE update 2016
Diagnostik - Moderation: M. Bürge, Zürich
Operative Therapie - Moderation: C. Tausch, Zürich
Über- oder Untertherapie? - Moderation: D. Fink, Zürich
Update Onkologie - Moderation: H-J. Senn, St. Gallen
Varia - Moderation: E. Saurenmann, Zürich
ELCC 2016 | European Lung Cancer Conference - ESMO
News
Osimertinib given as first-line treatment may alter biology of EGFR mutated non-small-cell lung cancer
Immunotherapy with live bacterium improves response rate in malignant pleural mesothelioma
Patients with EGFR expressing non-small-cell lung cancer benefit most from necitumumab added to chemotherapy
Studies confirm benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer
Interviews
3rd Gastrointestinal Cancer Conference
Thursday March 10
Session 1: Cystic Neoplasms of the Pancreas
Session 2: Biliary Tract - Extrahepatic Cholangiocarcinoma I
Keynote I: Molecular biology of pancreatic cancer
Session 3: Biliary Tract - Extrahepatic Cholangiocarcinoma II
Session 4: Cancer of the Ampulla of Vater
Friday March 11
Session 5: Understanding Pancreatic Cancer
Session 6: Resectable Pancreatic Cancer
Satellite symposium organized by Celgene
Session 7: Borderline Resectable Pancreatic Cancer
Session 8: Improving Outcome in Pancreatic Cancer
Symposium Nationale Strategie gegen Krebs:
WEF DAVOS: Cancer Moonshot: A Call to Action
Archiv 2015
SG-PRO 2015: 6. Interdisziplinäres Prostatakarzinomsymposium
I Grundlagen
II Das nodal positive Prostatakarzinom
III Metastasiertes Prostatakarzinom - neue Therapiemöglichkeiten
The European Cancer Congress 2015, Vienna September 25-29, 2015
Press Conference Highlights
Friday 25 September (09.30 hrs) in German
Friday 25 September (16.30 hrs) in English
Saturday 26 September (12.30 hrs) in English
Sunday 27 September (08.30 hrs) in English
Monday 28 September (11.30 hrs) in English
Statements & Interviews
15TH INTERNATIONAL MYELOMAWORKSHOP - SEPTEMBER 23-26, 2015
Press Conference Highlights
DIAGNOSTIC AND RESPONSE CRITERIA
NEWLY DIAGNOSED MULTIPLE MYELOMA YOUNG PATIENTS
RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
NEWLY DIAGNOSED MULTIPLE MYELOMA ELDERLY PATIENTS
IMMUNOTHERAPY
SPECIAL CONDITIONS
VIDEO-INTERVIEWS mit Christoph Driessen und Christian Taverna
WCGIC - 17th World Congress on Gastrointestinal Cancer
Metastatic Colorectal Cancer
Session XIX: Metastatic Colorectal Cancer
More Highlights in mCRC
Evaluating 1st-line treatment strategies for RAS WT mCRC
More Highlights
Multimodal management of patients with advanced cancer and cachexia
35. Jahrestagung Deutsche Gesellschaft für Senologie 25.–28. Juni 2015 Leipzig
Das Wichtigste vom Tage
Interviews
13th International Conference on Malignant Lymphoma
Highlights from 13-ICML
Plenary Session, June 17
Mundipharma Satellite Symposium at 13-ICML
Press Conference
SENOLOGIE update 2015
Radiologie - Moderation: R. Kubik, Baden
Brustzentren und Ärztenetzwerk - Moderation: C. Rageth, Zürich
Genetisches Mammakarzinom - Moderation: U. Breitenstein, Zürich
Update Therapie - Moderation: S. Aebi, Luzern
Varia - Moderation: C. Tausch, Zürich
14 th St. Gallen International Breast Cancer Conference
Interviews mit Fachleuten aus dem Bereich Brustkrebs
Christoph Thomssen, Halle(Saale) im Interview mit Doris C. Schmitt von Brustkrebs Deutschland e.V.
Christoph Thomssen, Halle(Saale) im Interview mit Doris C. Schmitt von Brustkrebs Deutschland e.V.
Michael Untch, Berlin-Buch im Interview mit Renate Haidinger, Brustkrebs Deutschland e.V.
Michael Untch, Berlin-Buch im Interview mit Renate Haidinger, Brustkrebs Deutschland e.V.
Ingo Bauerfeind, Landshut im Interview mit Renate Haidinger, Brustkrebs Deutschland e.V.
Ingo Bauerfeind, Landshut im Interview mit Renate Haidinger, Brustkrebs Deutschland e.V.
Ingo Bauerfeind, Landshut im Interview mit Renate Haidinger, Brustkrebs Deutschland e.V.
Christian Jackisch, Offenbach, im Interview mit Doris C. Schmitt von Brustkrebs Deutschland e.V.
Nadia Harbeck, München, im Interview mit Doris C. Schmitt von Brustkrebs Deutschland e.V.
Nadia Harbeck, München, im Interview mit Doris C. Schmitt von Brustkrebs Deutschland e.V.
Wednesday, 18 March 2015
Satellite symposium Nanostring Technologies
Opening ceremony and conferment of St.Gallen International Breast Cancer Award 2015 & Opening address by the St. Gallen 2015 Award winner
Session 1:
Session 2: Biology of breast cancer I:
Thursday, 19 March 2015
Session 3: Biology of breast cancer II:
Session 4: Biology of breast cancer III:
Session 5: Bridging clinic with biology:
Session 6:
Session 7:
Session 8:
Friday, 20 March 2015
Session 9:
Session 10: Radiotherapy:
Session 11: Adjuvant systemic treatment for individual patients I:
Session 12: Adjuvant systemic treatment for individual patients II:
Session 13: Adjuvant systemic treatment for individual patients III:
Saturday, 21 March 2015
Session 14:
Archiv 2014
ETOP Podium Discussion - Topics in Treatment of Lung Cancer
ESMO 2014, Madrid 26 - 30 September 2014
Presidential Symposium 1
Sandra Swain, Washington Cancer Institute, United States
Johan F. Vansteenkiste, University Hospitals Leuven - Campus Gasthuisberg, Belgium
Tony Mok, The Chinese University of Hong Kong, China
Presidential Symposium 2
Grant McArthur, Peter MacCallum Cancer Centre, Melbourne, Australia
Caroline Robert, Gustave Roussy, France
Jeffrey Weber, H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States
Melanoma
H. Kluger, M. Sznol, M. Callahan, M. Postow et al.
M. Taylor, J. Sosman, R. Gonzalez, M. Kittaneh et al.
O. Michielin (Lausanne, Switzerland)
A. Eggermont, V. Chiarion-Sileni, J. Grob, R. Dummer et al.
Anti-EGFR or anti-VEGF in first-line RAS wild-type metastastic CRC patients
H. Lenz, D. Niedzwiecki, F. Innocenti, C. Blanke et al.
A. Venook, D. Niedzwiecki, H. Lenz, M. Mahoney et al.
S. Stintzing, D. Modest, L. Fischer von Weikersthal, T. Decker et al.
Interview with PD Dr. med. Gunnar Folprecht, Universitätsklinikum Carl Gustav Carus, Dresden
Interview with Prof. Heinz-Josef Lenz, M.D., FACP, USC Norris Comprehensive Cancer Center, Los Angeles, USA
Interview with Prof. Dr. med. Volker Heinemann, Klinikum der Universität München, Klinikum Großhadern, München, Germany
Press briefings with Webcasts
Friday, 26 September 2014
Saturday, 27 September 2014
Sunday, 28 September 2014
Monday, 29 September 2014
Tuesday, 30 September 2014
1. Schweizer Krebskongress
Behandlungspfad: Schlagwort oder Realität?
Interdisziplinäre/interprofessionelle Zusammenarbeit
Nationale Strategie gegen Krebs: Erfahrungsbericht
Schlussvotum und Fazit
Interviews
"Wissen ist (m)eine Chance" eine Veranstaltung zum Thema "Metastasierter Brustkrebs"
WCGIC - 16th World Congress on Gastrointestinal Cancer
Metastatic Colorectal Cancer
More Highlights
34. Jahrestagung Deutsche Gesellschaft für Senologie 19.–21. Juni 2014 Berlin
Das Wichtigste vom Tage
Interviews
SENOLOGIE update 2014
Bildgebung
Pathologie, Molekularbiologie, Genetik
Adjuvante Therapie des Mammakarzinoms
Operative Therapie I
Operative Therapie II
Varia I
Varia II
International Diagnostic Course Davos 2014
Prostate Cancer: Update 2014
Interview with Prof. Dr. med. et Dr. h.c. Hedvig Hricak, Memorial Sloan-Kettering Cancer Center, New York
Per Skaane, Oslo, Norway: Tomosynthesis -
Ernst Wyrsch, Davos, CH:
16. Schweizer Onkologiepflege Kongress
Hauptvorträge
St. Gallen EORTC Gastrointestinal Cancer Conference 2014
Session 1: Understanding rectal cancer: Biological basis
Session 2: Staging of rectal cancer – early cancer
Session 3: Surgical treatment of rectal cancer I
Session 4: Combined modality therapy in rectal cancer
Session 5: Surgical treatment of rectal cancer II
Session 6: Issues in combined modality treatment for rectal cancer
Session 7: Rectal cancer with synchronous liver metastases
Session 8: Rectal cancer with synchronous liver metastases II
The 10th ESO colorectal cancer observatory
Keynote II: Effective combinations of targeted therapies for colon cancer based on insights in cross-talk between signaling pathways
The 8th Engadin Prostate Cancer Winter Symposium
1st Session - Chair: J. Hugosson, Sweden and F. Recker, CH
2nd Session - Chair: P. Albertsen, USA and Ch. Iselin, CH
3rd Session - Chair: L. Klotz, Canada and R. Grobholz, Switzerland
4th Session - Chair: M. Graefen, Germany and S. Wyler, Switzerland
5th Session - Chair: P. Hammerer, Germany and T. Sulser, Switzerland
6th Session - Chair: M. Emberton, the U.K. and P. Jichlinsky, Switzerland
7th Session - Chair: M. Emberton, the U.K. and P. Jichlinsky, Switzerland (Kopie)
8th Session - Chair: G. Lümmen, Germany and G. Thalmann, Switzerland
9th Session - Chair: M. Stöckle, Germany and M. Kwiatkowski, Switzerland
IBUS SEMINAR 2014
Friday morning sessions
Friday afternoon sessions
Saturday morning sessions
Saturday afternoon sessions
Livecasts & Kongresskalender
Livecast
Kongresskalender 2020
Drugs oral & i.v., Guidelines, Interaktionen
Orale Krebstherapeutika
orale Wirkstoffe A
orale Wirkstoffe B
Orale Wirkstoffe C
Orale Wirkstoffe D
Orale Wirkstoffe E
Orale Wirkstoffe G
Orale Wirkstoffe H
Orale Wirkstoffe I
Orale Wirkstoffe L
Orale Wirkstoffe Ν
Orale Wirkstoffe O
Orale Wirkstoffe P
Orale Wirkstoffe R
Orale Wirkstoffe S
Orale Wirkstoffe T
Orale Wirkstoffe U
Orale Wirkstoffe V
Orale Wirkstoffe Z
Alle Wirkstoffe
Melden Sie fehlende Wirkstoffe
Acronyme
ALK-Inhibitors
Wirkstoffe A
Wirkstoffe B
Wirkstoffe C
Wirkstoffe D
Wirkstoffe E
Wirkstoffe F
Wirkstoffe G
Wirkstoffe H
Wirkstoffe I
Wirkstoffe K
Wirkstoffe L
Wirkstoffe M
Wirkstoffe N
Wirkstoffe O
Wirkstoffe P
Wirkstoffe Q
Wirkstoffe R
Wirkstoffe S
Wirkstoffe T
Wirkstoffe U
Wirkstoffe V
Wirkstoffe Z
Behandlungsguidelines
Journal of Oncoletter
The Cancer Cell Line Encyclopedia
Texte zur Medizinischen Onkologie aus dem Swiss Medical Forum
Oncologic emergencies
Interaktionsprüfungen
Krebserkrankungen (Entstehung & Verlauf)
Krebserkrankungen B
Krebserkrankungen D
Krebserkrankungen E
Krebserkrankungen G
Krebserkrankungen H
Krebserkrankungen L
Krebserkrankungen M
Krebserkrankungen N
Krebserkrankungen P
Krebserkrankungen S
Wissenschaftlicher Beirat Oncoletter
Nebenwirkungen & Behandlungs- vorschläge
Symptome
Allgemeine Störungen
Fatigue
Fieber/Infektion
Ödeme
Schmerzen
Stimmungsschwankungen
Atmungsorgane
Dyspnoe
Epistaxis/Nasenbluten
Pleuraerguss
Augen
Konjunktivitis
Periorbitale Oedeme
Sehstoerungen
Blut- und Lymphsystem
Anaemie
Lymphopenie
Neutropenie
Thrombozytopenie
Gastrointestinale Störungen
Abdominalschmerz
Diarrhoe
Dyspepsie
Mukositis/Stomatitis
Nausea und Erbrechen
Obstipation
Haut
Aktinische Keratose
Alopezie
Hand-Fuss-Syndrom
Hyperkeratose
Photosensivitätsreaktion
Plattenepithelkarzinom der Haut
Praevention von Pruritus, Rash, Desquamation
Pruritus
Rash, papulopustulöse, follikuläre Exantheme
Seborrhoische Keratose
Sonnenbrand
Trockene Haut
Herz, Gefässe
Arterielle Hypertonie
Blutungen
Herzinsuffizienz
Hitzewallungen
Verminderung der linksventrikulären Auswurfsfraktion (LVEF)
Leber und Galle
Dosierungsempfehlungen oraler TKI/mTor-Inhibitoren bei Leberdysfunktion
Gamma-Glutamyl-Transferase
Muskelskelettsystem
Arthralgien
Knochenschmerzen
Muskelschwaeche
Muskelverhaertungen und Muskelkraempfe
Muskuloskelettale Beschwerden/Schmerzen in den Extremitaeten/Gliederschmerzen
Myalgie/Muskelschmerzen
Rueckenschmerzen
Nervensystem
Dysgeusie
Insomnie
Kopfschmerzen
Neuropathie/Polyneuropathie
Reversible posteriore Leukenzephalopathie
Niere und ableitende Harnwege
Harnwegsinfekt
Stoffwechsel- und Ernährungsstörungen
Amylase-/Lipasewerte
Anorexie
Cholesterol- oder Triglyzeridwerte
Gewichtszunahme
Glucosewerte
Hypokaliämie
Hypokalzämie
Hypophosphatämie
Hypothyreose
Referenzen
Nutzungsbestimmungen
Organisationen
Fachgesellschaften
Info für PatientINNen
Netzwerke
Startseite
Kongressberichte & Archiv
Virtual Edition of the 25th Annual Congress of the European Hematology Association
Oral Sessions
Chronic Myeloid Neoplasms
MDS:
Navigation überspringen
MDS:
Novel Treatments I
MDS:
Novel Treatments II
Navigation überspringen
The 22nd ESMO World Congress on Gastrointestinal Cancer - Virtual Congress
Virtual Edition of the 25th Annual Congress of the European Hematology Association
Presidential Symposium
Plenary Session I
Plenary Session II
Late-Breaking Oral Session - available fromSaturday June 13 8.30 AM
Oral Sessions
Acute Leukemia
Lymphoma
Chronic Myeloid Neoplasms
CML clinical
MDS:
MDS:
MDS:
MPN (Myelofibrosis & Hypereosinophilic Syndrome)
Chronic Lymphoid Neoplasms
Immunology
Red & White Cell Disorders
ITP:
Link to Satellite Session - Live Fri 12 Jun 17:30-18:30
e-Poster Presentations
ASCO20 Virtual Scientific Meeting
SAMO Virtual Workshop on COVID19:
Coronavirus/Brustkrebs
AGO MAMMAKARZINOM - State of the Art Meeting 2020
Ten Years of ETOP
2nd Zurich Brain Metastasis Symposium
SABCS - 42nd Annual San Antonio Breast Cancer Symposium
61st ASH Annual Meeting and Exposition
CAR-T-Zell Therapie in der Schweiz
Archiv 2019
Archiv 2018
Archiv 2017
Archiv 2016
Archiv 2015
Archiv 2014
News
Abemaciclib+fulvestrant, and trastuzumab: significantly improved PFS vs standard-of-care chemotherapy and trastuzumab
22-06-2020 15:21
Weiterlesen ...
Tucatinib (Tukysa), Cemiplimab (Libtayo®), Larotrectinib (Vitrakvi®) in der Schweiz jetzt zugelassen
10-06-2020 10:36
Weiterlesen ...
Am Universitätsspital Basel ist der erste Prostatakarzinom-Patient mit Lutetium-177-PSMA behandelt worden
05-06-2020 17:02
Weiterlesen ...
Newsletter
Firstname
Name
E-Mail*
Arzt*
Ja
Nein
Neu laden
Bitte geben Sie den Schriftzug ein!
